



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**


(86) Date de dépôt PCT/PCT Filing Date: 2016/10/13
 (87) Date publication PCT/PCT Publication Date: 2017/04/20
 (85) Entrée phase nationale/National Entry: 2018/04/12
 (86) N° demande PCT/PCT Application No.: US 2016/056875
 (87) N° publication PCT/PCT Publication No.: 2017/066468
 (30) Priorité/Priority: 2015/10/13 (US62/240,810)

(51) Cl.Int./Int.Cl. *C12N 1/19* (2006.01),
A61K 35/74 (2015.01), *A61K 39/40* (2006.01),
A61P 1/12 (2006.01), *A61P 31/00* (2006.01),
C07K 16/12 (2006.01), *C07K 16/16* (2006.01),
C07K 16/46 (2006.01), *C12N 15/13* (2006.01),
C12N 15/81 (2006.01), *C12P 21/08* (2006.01)
 (71) Demandeur/Applicant:
 UNIVERSITY OF MARYLAND, BALTIMORE, US
 (72) Inventeurs/Inventors:
 FENG, HANPING, US;
 GALEN, JAMES EUGENE, US;
 CHEN, KEVIN, US;
 ZHU, YIXUAN, US
 (74) Agent: FASKEN MARTINEAU DUMOULIN LLP

(54) Titre : IMMUNOTHERAPIE A BASE DE LEVURE CONTRE UNE INFECTION A CLOSTRIDIUM DIFFICILE
 (54) Title: YEAST-BASED IMMUNOTHERAPY AGAINST CLOSTRIDIUM DIFFICILE INFECTION

Figure 20

C



(57) **Abrégé/Abstract:**

Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid V_HH peptide monomers, linked groups of V_HH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and V_HH peptide monomers joined to IgG antibodies.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
20 April 2017 (20.04.2017)(10) International Publication Number
WO 2017/066468 A1

(51) International Patent Classification:

A61P 1/12 (2006.01) C07K 16/16 (2006.01)
C07K 16/12 (2006.01) C07K 16/46 (2006.01)

(21) International Application Number:

PCT/US2016/056875

(22) International Filing Date:

13 October 2016 (13.10.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/240,810 13 October 2015 (13.10.2015) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF MARYLAND, BALTIMORE** [US/US]; 620 West Lexington Street, 4th floor, Baltimore, Maryland 21201 (US).

(72) Inventors; and

(71) Applicants (for US only): **FENG, Hanping** [US/US]; 5311 Honey Court, Ellicott City, Maryland 21043 (US). **GALEN, James Eugene** [US/US]; 5807 Victor Drive, Eldersburg, Maryland 21784-8439 (US). **CHEN, Kevin** [CN/US]; 1630 Whetstone Way Apt 408, Baltimore, Maryland 21230 (US). **ZHU, Yixuan** [CN/US]; 4706 Rams Horn Row, Ellicott City, Maryland 21042 (US).(74) Agent: **HISSONG, Drew**; Wenderoth, Lind & Ponack LLP, 1030 15th St NW, Suite 400 East, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: YEAST-BASED IMMUNOTHERAPY AGAINST CLOSTRIDIUM DIFFICILE INFECTION

Figure 20

C

(57) Abstract: Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing *Clostridium difficile* infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to *Clostridium difficile* toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid V_HH peptide monomers, linked groups of V_HH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and V_HH peptide monomers joined to IgG antibodies.

WO 2017/066468 A1

YEAST-BASED IMMUNOTHERAPY AGAINST CLOSTRIDIUM DIFFICILE INFECTION

STATEMENT OF FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

[0001] This invention was made with government support under Grant Numbers DK084509 and AI109776 awarded by the National Institutes of Health. The government has certain rights in the invention.

SEQUENCE LISTING

[0002] A sequence listing in electronic (ASCII text file) format is filed with this application and incorporated herein by reference. The name of the ASCII file is "2016_1343A_ST25.txt"; the file was created on October 13, 2016; the size of the file is 407 KB.

BACKGROUND

[0003] The bacterium *Clostridium difficile* is the most common cause of nosocomial antibiotic-associated diarrhea as well as the etiologic agent of pseudomembranous colitis [1]. It is estimated that over 500,000 cases of *C. difficile*-associated disease (CDI) occur annually in the United States, with the annual mortality rate ranging from about 3-17%, depending on the strains. With the emergence of hypervirulent and antibiotic-resistant strains, the incidence of mortality in CDI patients is increasing rapidly [2].

[0004] CDI is mainly caused by the two *C. difficile* exotoxins TcdA and TcdB (as TcdA-TcdB- strains are avirulent) [21,22]. The two toxins are structurally similar and exhibit a similar mode of action on host cells. Both toxins target host Rho GTPases, leading to their inactivation as well as cytoskeleton disorganization. The relative roles of the two toxins in the pathogenesis of CDI are not well understood, but it is clear that either toxin individually can cause CDI in animals [22,23].

[0005] The options for treating CDI patients are limited and the recurrence rate is high (20-35% of patients). Current standard treatment for CDI using antibiotics causes the disruption of microflora and results in a relapse rate approaching 35% [3,13]. While other interventions have been tried (e.g., probiotics, toxin-absorbing polymers, and toxoid vaccines), neither prevention nor treatment strategies have kept up with the increased incidence and severity of this infection.

The risk of further episodes of CDI in recurrent patients can be more than 50% [14] and a subset of patients will have multiple recurrences. Recurrent CDI can be caused by the same strain or newly colonizing strains [15-18].

[0006] Newer immune-based therapies have been shown to be somewhat effective in clinical trials, including intravenous immunoglobulin (IVIG) against severe CDI [4-8] and human monoclonal antibodies against recurrent CDI [9]. Fidaxomicin, a narrow spectrum macrocyclic antibiotic, showed an effect similar to oral vancomycin on CDI but was significantly better at lowering the relapse rate [10]. Fecal transplantation is effective against refractory and recurrent CDI, but it is difficult to standardize and it is associated with risks [11,12].

[0007] CDI is a frustrating condition that is difficult to treat and may affect patients for months or even years, causing tremendous morbidity and mortality [19]. Accordingly, there is a need for new treatments for CDI, and means for preventing both primary and recurrent CDI in subjects at risk of developing CDI.

BRIEF SUMMARY OF INVENTION

[0008] Provided herein are antibody-based fusion protein binding agents that selectively bind *C. difficile* virulence factors TcdA and TcdB, and strains of the probiotic yeast *Saccharomyces* genetically engineered to express and secrete these *C. difficile* toxin binding agents. Both the yeast and the binding agents show utility in treating and preventing primary and recurrent CDI in a subject. Orally administered *Saccharomyces* secreting the binding agents in host intestines can relieve ongoing CDI and prevent recurrence.

[0009] The present invention is thus directed to *C. difficile* toxin binding agents, strains of *Saccharomyces* including, but not limited to, *Saccharomyces boulardii* engineered to produce the binding agents, methods of making the engineered strains of yeast, and methods of treating and preventing primary and recurrent CDI using the binding agents and the engineered strains of yeast, among other important features.

Binding Agents

[0010] The binding agents of the present invention include simple V_HH peptide monomers and linked groups of V_HH peptide monomers (comprising 2, 3, 4, or more monomers), as well as

more complex binding agents that comprise V_HH peptide monomers joined to antibody Fc domains, as well as V_HH peptide monomers joined to partial or full IgG antibodies.

[0011] In a first embodiment, the present invention is directed to binding agents comprising V_HH peptide monomers and linked groups of V_HH peptide monomers comprising two, three, four, or more monomers, each of which binds TcdA and/or TcdB, preferably with specificity. Thus, the invention encompasses V_HH peptide binding agents comprising at least one V_HH peptide monomer, wherein each V_HH peptide monomer has binding specificity for an epitope of *C. difficile* toxin A (TcdA) or toxin B (TcdB). In certain aspects, these binding agents comprise two, three, four, or more linked V_HH peptide monomers. The V_HH peptide monomers include, but are not limited to, the V_HH peptide monomers 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5), and AH3 (SEQ ID NO:7).

[0012] In aspects of this embodiment where two or more monomer are linked, the monomers may be linked by flexible peptide linkers, generally comprising between 10 and 20 amino acids. Suitable linkers include, but are not limited to, linker-1 (SEQ ID NO:9), linker-2 (SEQ ID NO:11), and linker-3 (SEQ ID NO:13).

[0013] In certain aspects of this embodiment, the binding agents bind to TcdA and/or TcdB with specificity. In certain aspects of this embodiment, the binding agents exhibit TcdA and/or TcdB neutralizing activity.

[0014] In a specific aspect of this embodiment, the binding agent comprises four linked V_HH peptide monomers where two of the monomers have binding specificity for epitopes of TcdA and two of the monomers have binding specificity for epitopes of TcdB. The epitopes of TcdA may be the same or different. The epitopes of TcdB may be the same or different.

[0015] In a specific aspect of this embodiment, the binding agent comprises the amino acid sequence set forth in SEQ ID NO:19 or a sequence variant thereof having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both. In some instances, variant amino acids of the sequence variant are located in framework regions of the V_HH peptide monomers.

[0016] In a second embodiment, the invention is directed to binding agents comprising V_HH peptide monomers joined to IgG antibodies, where the binding agents bind TcdA and/or TcdB.

In these IgG-based binding agents, the variable regions of the light and heavy chains of IgG antibodies are replaced by one, two, three, four or more of the V_HH peptide monomers.

[0017] In certain aspects of this embodiment, these binding agents comprise two, three, four, or more linked V_HH peptide monomers joined to the amino termini of IgG light and heavy chains in place of the variable regions. The V_HH peptide monomers include, but are not limited to, the V_HH peptide monomers 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5), and AH3 (SEQ ID NO:7).

[0018] In aspects of this embodiment where two or more monomer are linked, the monomers may be linked by flexible peptide linkers, generally comprising between 10 and 20 amino acids. Suitable linkers include, but are not limited to, linker-1 (SEQ ID NO:9), linker-2 (SEQ ID NO:11), and linker-3 (SEQ ID NO:13).

[0019] In a first sub-embodiment, the invention is directed to tetra-specific, octameric binding agents comprising an IgG antibody, two sets of linked first and second V_HH peptide monomers, and two sets of linked third and fourth V_HH peptide monomers, wherein the IgG antibody comprises two arms, each arm comprising a heavy chain lacking a variable region and a light chain lacking a variable region, and each chain having an amino terminus, wherein for each arm of the antibody, one set of linked first and second V_HH peptide monomers is joined to the amino terminus of the light chain, and one set of linked third and fourth V_HH peptide monomers is joined to the amino terminus of the heavy chain, and wherein the V_HH peptide monomers have binding specificity for an epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB). This binding agent is termed “tetra-specific” as it recognizes four different toxin epitopes. It is termed “octameric” as it bears eight V_HH peptide monomers (two copies of the first monomer, two copies of the second monomer, two copies of the third monomer, and two copies of the fourth monomer).

[0020] In this sub-embodiment, the first, second, third and fourth V_HH peptide monomers each has binding specificity for a different epitope.

[0021] In certain aspects of this sub-embodiment, two of the V_HH peptide monomers have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers have binding specificity for epitopes of TcdB.

[0022] In certain aspects of this sub-embodiment, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[0023] In a specific aspect of this sub-embodiment, the light (kappa) chain of the binding agent comprises the amino acid sequence set forth in SEQ ID NO:46 (AA6/E3 kappa) or a sequence variant having at least 95% sequence identity thereto, and the heavy chain of the binding agent comprises the amino acid sequence set forth in SEQ ID NO:44 (AH3/5D heavy) or a sequence variant having at least 95% sequence identity thereto. As this binding agent is an IgG-based binding agent, it will be clear to the skilled artisan that two heavy chain polypeptides and two light chain polypeptides, having the noted amino acid sequences, will assemble through disulfide bonding to provide the complete binding agent. The sequence variants retain TcdA and/or TcdB binding specificity, or the sequence variants retain toxin-neutralizing activity, or both. The variant amino acids of the sequence variants may be located in framework regions of the V_HH peptide monomers.

[0024] In a second sub-embodiment, the invention is directed to bi-specific or tetra-specific, tetrameric binding agents comprising an IgG antibody and first, second, third and fourth V_HH peptide monomers, wherein the IgG antibody comprises two arms, each arm comprising a heavy chain lacking a variable region and a light chain lacking a variable region, and each chain having an amino terminus, wherein for a first arm of the antibody, the first V_HH peptide monomer is joined to the amino terminus of the light chain, and the second V_HH peptide monomer is joined to the amino terminus of the heavy chain, wherein for a second arm of the antibody, the third V_HH peptide monomer is joined to the amino terminus of the light chain, and the fourth V_HH peptide monomer is joined to the amino terminus of the heavy chain, and wherein the V_HH peptide monomers have binding specificity for an epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB). When the binding agent is “tetra-specific”, it recognizes four different toxin epitopes; when “bi-specific” it recognizes two different toxin epitopes. The binding agents are “tetrameric” as they bear four V_HH peptide monomers (when bi-specific, the first and third monomer have the same sequence and bind the same epitope, and the second and fourth monomers have the same sequence and bind the same epitope; when tetra-specific, each of the monomers has a different sequence and binds a different epitope).

[0025] When the binding agent is bi-specific, the first and second monomers have binding specificity for different epitopes, the first and third monomers have identical amino acid sequences, and the second and fourth monomers have identical amino acid sequences. One of the V_HH peptide monomers may have binding specificity for an epitope of TcdA and one of the V_HH peptide monomers may have binding specificity for an epitope of TcdB.

[0026] When the binding agent is tetra-specific, each of the V_HH peptide monomers has binding specificity for a different epitope. Two of the V_HH peptide monomers may have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers may have binding specificity for epitopes of TcdB.

[0027] In certain aspects of this sub-embodiment, each of the V_HH peptide monomers has binding specificity for epitopes of TcdA.

[0028] In certain aspects of this sub-embodiment, each of the V_HH peptide monomers has binding specificity for epitopes of TcdB.

[0029] In certain aspects of this sub-embodiment, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[0030] In a specific aspect of this sub-embodiment, the light (kappa) chain of the binding agent comprises the amino acid sequence set forth in SEQ ID NO:40 (AA6 kappa) or a sequence variant having at least 95% sequence identity thereto, and the heavy chain of the binding agent comprises the amino acid sequence set forth in SEQ ID NO:36 (AH3 heavy) or a sequence variant having at least 95% sequence identity thereto. As this binding agent is an IgG-based binding agent, it will be clear to the skilled artisan that two heavy chain polypeptides and two light chain polypeptides, having the noted amino acid sequences, will assemble through disulfide bonding to provide the complete binding agent. The sequence variants retain TcdA and/or TcdB binding specificity, or the sequence variants retain toxin neutralizing activity, or both. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[0031] In another specific aspect of this sub-embodiment, the light (kappa) chain of the binding agent comprises the amino acid sequence set forth in SEQ ID NO:42 (E3 kappa) or a sequence variant having at least 95% sequence identity thereto, and the heavy chain of the binding agent comprises the amino acid sequence set forth in SEQ ID NO:38 (5D heavy) or a

sequence variant having at least 95% sequence identity thereto. As this binding agent is an IgG-based binding agent, it will be clear to the skilled artisan that two heavy chain polypeptides and two light chain polypeptides, having the noted amino acid sequences, will assemble through disulfide bonding to provide the complete binding agent. The sequence variants retain TcdA and/or TcdB binding specificity, or the sequence variants retain toxin neutralizing activity, or both. The variant amino acids of the sequence variants may be located in framework regions of the V_HH peptide monomers.

[0032] In certain aspects of this embodiment and the sub-embodiments, the binding agents bind to TcdA and/or TcdB with specificity. In certain aspects of this embodiment, the binding agents exhibit TcdA and/or TcdB neutralizing activity.

[0033] In a third embodiment, the invention is directed to binding agents comprising V_HH peptide monomers joined to antibody Fc domains, where the binding agents bind TcdA and/or TcdB. In these Fc domain-based binding agents, one, two, three, four or more of the V_HH peptide monomers are joined to the hinge, C_H2 and C_H3 regions of each arm of Fc domain of an antibody heavy chain. Thus, the peptide monomers replace the Fab regions of an antibody.

[0034] In certain aspects of this embodiment, these binding agents comprise two, three, four, or more linked V_HH peptide monomers joined to the amino termini of the arms of the Fc domains. The V_HH peptide monomers include, but are not limited to, the V_HH peptide monomers 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5) and AH3 (SEQ ID NO:7).

[0035] In aspects of this embodiment where two or more monomer are linked, the monomers may be linked by flexible peptide linkers, generally comprising between 10 and 20 amino acids. Suitable linkers include, but are not limited to, linker-1 (SEQ ID NO:9), linker-2 (SEQ ID NO:11), and linker-3 (SEQ ID NO:13).

[0036] In a first sub-embodiment, the invention is directed to tetra-specific, octameric binding agents comprising an antibody Fc domain and two sets of linked first, second, third and fourth V_HH peptide monomers, wherein the antibody Fc domain comprises two arms, each arm comprising hinge, C_H2 and C_H3 regions of an antibody heavy chain, and each arm having an amino terminus, wherein for each arm of the Fc domain, one set of linked first, second, third and fourth V_HH peptide monomers is joined to the amino terminus of the arm, and where the V_HH peptide monomers have binding specificity for an epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB). This binding agent is termed “tetra-specific” as it recognizes four different

toxin epitopes. It is termed “octameric” as it bears eight V_HH peptide monomers (two copies of the first monomer, two copies of the second monomer, two copies of the third monomer, and two copies of the fourth monomer).

[0037] In certain aspects of this sub-embodiment, the first, second, third and fourth V_HH peptide monomers each has binding specificity for a different epitope.

[0038] In certain aspects of this sub-embodiment, two of the V_HH peptide monomers have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers have binding specificity for epitopes of TcdB.

[0039] In certain aspects of this sub-embodiment, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[0040] In a specific aspect of this sub-embodiment, the binding agent comprises the amino acid sequence set forth in SEQ ID NO:22 (ABAB-Fc) or a sequence variant having at least 95% sequence identity thereto, where the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both. As this binding agent is an Fc domain-based binding agent, it will be clear to the skilled artisan that two identical polypeptides, having the noted amino acid sequence, serve as the arms of the binding agent and that the arms will assemble through disulfide bonding to provide the complete binding agent. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[0041] In a second sub-embodiment, the invention is directed to bi-specific, tetrameric binding agents comprising an antibody Fc domain and two sets of linked first and second V_HH peptide monomers, wherein the antibody Fc domain comprises two arms, each arm comprising hinge, C_H2 and C_H3 regions of an antibody heavy chain, and each arm having an amino terminus, wherein for each arm of the Fc domain, one set of linked first and second V_HH peptide monomers is joined to the amino terminus of the arm, and where the V_HH peptide monomers have binding specificity for an epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB). This binding agent is termed “bi-specific” as it recognizes two different toxin epitopes. It is termed “tetrameric” as it bears four V_HH peptide monomers (two copies of the first monomer, and two copies of the second monomer).

[0042] In certain aspects of this sub-embodiment, the first and second V_HH peptide monomers have binding specificity for the same or different epitopes.

[0043] In certain aspects of this sub-embodiment, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[0044] In a specific aspect of this sub-embodiment, the binding agent comprises the amino acid sequence set forth in SEQ ID NO:32 (AH3/5D-Fc) or a sequence variant having at least 95% sequence identity thereto, where the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both. As this binding agent is an Fc domain-based binding agent, it will be clear to the skilled artisan that two identical polypeptides, having the noted amino acid sequence, serve as the arms of the binding agent and that the arms will assemble through disulfide bonding to provide the complete binding agent. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[0045] In another specific aspect of this sub-embodiment, the binding agent comprises the amino acid sequence set forth in SEQ ID NO:34 (AA6/E3-Fc) or a sequence variant having at least 95% sequence identity thereto, where the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both. As this binding agent is an Fc domain-based binding agent, it will be clear to the skilled artisan that two identical polypeptides, having the noted amino acid sequence, serve as the arms of the binding agent and that the arms will assemble through disulfide bonding to provide the complete binding agent. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[0046] In certain aspects of this embodiment and the sub-embodiments, the binding agents bind to TcdA and/or TcdB with specificity. In certain aspects of this embodiment, the binding agents exhibit TcdA and/or TcdB neutralizing activity.

[0047] The invention includes humanized variants of each the binding agents provided in the various embodiments and aspects defined herein. Likewise, the invention includes epitope binding fragments of each the binding agents provided in the various embodiments and aspects defined herein.

Polynucleotides, Expression Vectors, and Host Cells

[0048] The invention includes polynucleotides comprising nucleotide sequences encoding each the binding agents provided in the various embodiments and aspects defined herein, as well as complementary strands thereof. The invention also includes expression vectors (e.g., bacterial and yeast) comprising the polynucleotides, and host cells (e.g., bacterial, yeast, mammalian, insect) comprising the expression vectors. The invention further includes methods of producing the binding agents defined herein, comprising culturing the host cells under conditions promoting expression of the binding agents encoded by the expression vectors, and recovering the binding agents from the cell cultures.

Engineered Strains of *S. boulardii*

[0049] In a fourth embodiment, the invention is directed to strains of *Saccharomyces* yeast, such as *S. cerevisiae* and *S. boulardii*, engineered to produce one or more of the binding agents defined herein. In preferred aspects, the engineered strains of *Saccharomyces* yeast secrete the binding agents.

[0050] The identity of the *Saccharomyces* yeast strain is only limited in that it can be engineered to produce, and preferably secrete, one or more of the binding agents of the invention. In preferred aspects of the invention, the strain of *Saccharomyces* yeast engineered to produce one or more of the binding agents is *S. cerevisiae* or *S. boulardii*. The invention thus encompasses an engineered strain of *S. cerevisiae* that produces one or more of the binding agents defined herein, as well as an engineered strain of *S. cerevisiae* that secretes one or more of the binding agents defined herein. The invention also encompasses an engineered strain of *S. boulardii* that produces one or more of the binding agents defined herein, as well as an engineered strain of *S. boulardii* that secretes one or more of the binding agents defined herein.

[0051] In an example of this embodiment, the invention is directed to engineered strains of *Saccharomyces* yeast that produce a binding agent comprising a V_HH peptide monomer or linked groups of V_HH peptide monomers comprising two, three, four, or more monomers, each of which binds TcdA and/or TcdB, preferably with specificity. Thus, the invention encompasses engineered strains of *Saccharomyces* yeast that produces V_HH peptide binding agents comprising at least one V_HH peptide monomer, wherein each V_HH peptide monomer has binding specificity for an epitope of *C. difficile* toxin A (TcdA) or toxin B (TcdB). In certain aspects, these binding

agents comprise two, three, four, or more linked V_HH peptide monomers. The V_HH peptide monomers include, but are not limited to, the V_HH peptide monomers 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5), and AH3 (SEQ ID NO:7).

[0052] In another example of this embodiment, the invention is directed to engineered strains of *Saccharomyces* yeast that produce binding agents comprising V_HH peptide monomers joined to IgG antibodies, where the binding agents bind TcdA and/or TcdB, as defined herein. In these IgG-based binding agents, the variable regions of the light and heavy chains of IgG antibodies are replaced by one, two, three, four or more of the V_HH peptide monomers.

[0053] In further example of this embodiment, the invention is directed to engineered strains of *Saccharomyces* yeast that produce binding agents comprising V_HH peptide monomers joined to antibody Fc domains, where the binding agents bind TcdA and/or TcdB, as defined herein. In these Fc domain-based binding agents, one, two, three, four or more of the V_HH peptide monomers are joined to the hinge, C_H2 and C_H3 regions of each arm of Fc domain of an antibody heavy chain. Thus, the peptide monomers replace the Fab regions of an antibody.

[0054] In yet another example of this embodiment, the invention is directed to an engineered strain of *Saccharomyces* yeast that produces a tetra-specific, tetrameric binding agent, wherein the binding agent comprises linked first, second, third and fourth V_HH peptide monomers, and wherein the V_HH peptide monomers independently have binding specificity for an epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB). In certain aspects, the first, second, third and fourth V_HH peptide monomers each has binding specificity for a different epitope. In certain aspects, the two of the V_HH peptide monomers have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers have binding specificity for epitopes of TcdB. In certain aspects, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[0055] In a preferred example of this embodiment, the invention is directed to an engineered strain of yeast, wherein the binding agent is ABAB, wherein the first and third monomers have binding specificity for epitopes of TcdA and the first and third monomers are V_HH peptide monomers AH3 (SEQ ID NO:7) and AA6 (SEQ ID NO:5), respectively, and wherein the second and fourth monomers have binding specificity for epitopes of TcdB and the second and fourth monomers are V_HH peptide monomers 5D (SEQ ID NO:1) and E3 (SEQ ID NO:3), respectively.

In certain aspects, the ABAB binding agent comprises the amino acid sequence set forth in SEQ ID NO:19, or a sequence variant having at least 95% sequence identity thereto, wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both. In certain aspects, the ABAB binding agent further comprises an N-terminal secretion signal selected from the AT secretion signal (MRFPSIFTAVLFAASSALA (SEQ ID NO:99)) and the IVS secretion signal (MLLQAFLFLLAGFAAKISA (SEQ ID NO:103)).

[0056] In certain aspects, the ABAB binding agent is expressed from a plasmid within the yeast, wherein the ABAB binding agent comprises the amino acid sequence set forth in SEQ ID NO:107, or a sequence variant having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both. The plasmid may be, but is not limited to, pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88).

[0057] In certain aspects, the ABAB binding agent coding sequence is integrated into a chromosome of the strain of yeast, wherein the ABAB binding agent comprises the amino acid sequence set forth in SEQ ID NO:109, or a sequence variant having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.

[0058] Aspects of this embodiment include engineered strains of *Saccharomyces* yeast that produce a therapeutic protein having binding specificity for a unique epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB), or both. Preferably, the engineered strain of *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*. A therapeutic protein is any protein that can bring about an improvement or cure in a medical condition in a subject, or that can inhibit or prevent a medical condition from developing in a subject. Suitable therapeutic protein include, but are not limited to, proteins that (a) replace a protein that is deficient or abnormal; (b) augment an existing pathway; (c) provide a novel function or activity; (d) interfere with a molecule or organism; and (e) deliver other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector proteins. Therapeutic proteins also include antibodies and antibody-based drugs, Fc fusion proteins, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics. Therapeutic proteins further include bispecific monoclonal antibodies (mAbs) and

multispecific fusion proteins, mAbs conjugated with small molecule drugs, and proteins with optimized pharmacokinetics.

Methods of Making Engineered Strains of *S. boulardii*

[0059] The invention is also directed to methods of making strains of *Saccharomyces* yeast engineered to produce one or more of the binding agents defined herein.

[0060] The invention thus encompasses a method of preparing a strain of *Saccharomyces* yeast engineered to produce one or more of the binding agents defined herein comprising (a) transforming a strain of *Saccharomyces* yeast with an expression vector encoding the binding agent, and (b) screening the yeast of (a) for production of the binding agent. In a certain aspect, the expression vector is plasmid pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88).

[0061] The invention thus encompasses a method of preparing a strain of *Saccharomyces* yeast engineered to produce one or more of the binding agents defined herein comprising (a) chromosomally integrating a polynucleotide sequence encoding the binding agent into the genome of the strain of *Saccharomyces* yeast, and (b) screening the yeast of (a) for production of the binding agent. In certain aspects, the chromosomal integration is performed via:

(a) amplifying a polynucleotide sequence encoding the ABAB binding agent from plasmid pCEV-G4-Km-TEF-AT-yABAB hAA6T83N-tagless (SEQ ID NO:90) using primers containing (i) nucleic acid sequence homologous to a selected yeast chromosomal integration site and (ii) nucleic acid sequence homologous to regions 5' and 3' of ABAB binding agent coding sequence of the plasmid, to produce an integration cassette,

(b) transforming yeast with the integration cassette produced in (a) with pCRI-Sb- δ 1 (SEQ ID NO:91) or pCRI-Sb- δ 2 (SEQ ID NO:92) to induce a double stranded break within the corresponding yeast chromosomal delta sites under conditions promoting spontaneous integration of the integration cassette into the site of the double stranded break,

(c) screening the transformed yeast of (b) for production of the ABAB binding agent.

[0062] In certain aspects of these methods, the strain of *Saccharomyces* yeast engineered to produce the binding agents is an auxotrophic strain of *Saccharomyces* yeast, such as a *ura3-* strain of yeast. A *ura3-* strain of yeast can be utilized under *ura3* selection.

[0063] In certain aspects of these methods, the strain of *Saccharomyces* yeast engineered to produce the binding agents is *S. cerevisiae* or *S. boulardii*.

[0064] In certain aspects of these methods, the screening is performed using an immunoassay, such as an ELISA.

Pharmaceutical Formulations

[0065] The invention includes pharmaceutical formulations comprising one or more of the binding agents defined herein and a pharmaceutically acceptable carrier or diluent. The invention also includes pharmaceutical formulations comprising one or more of the engineered strains of *Saccharomyces* yeast defined herein and a pharmaceutically acceptable carrier or diluent. In certain aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

Methods of Treating and Preventing

[0066] In a sixth embodiment, the invention is directed to methods of treating or preventing a disease symptom induced by *C. difficile* in a subject comprising administering a therapeutically-effective amount of one or more binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[0067] In certain aspects of this embodiment, the disease symptom induced by *C. difficile* is diarrhea.

[0068] In a seventh embodiment, the invention is directed to methods of neutralizing *C. difficile* toxin TcdA and/or TcdB in a subject infected by *C. difficile* comprising administering a therapeutically-effective amount of one or more binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject having *C. difficile* infection. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[0069] In an eighth embodiment, the invention is directed to methods of treating or preventing *C. difficile* infection in a subject comprising administering a therapeutically-effective amount of one or more of the binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*. In certain aspects of the eighth embodiment, the method further comprises administering a therapeutically-effective amount of an antibiotic to the subject.

[0070] In a ninth embodiment, the invention is directed to methods of maintaining normal bowel function in a subject having a *C. difficile* infection comprising administering a therapeutically-effective amount of one or more of the binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*. In certain aspects of the ninth embodiment, the method further comprises administering a therapeutically-effective amount of an antibiotic to the subject.

[0071] In certain aspects of the methods, the binding agent is in a pharmaceutical formulation comprising the binding agent and a pharmaceutically acceptable carrier or diluent.

[0072] In certain aspects of the methods, the therapeutically-effective amount of the binding agent is between 10 ug/kg and 100 mg/kg of the agent per body weight of the subject.

[0073] In certain aspects of the methods, the agent is administered to the subject orally, parenterally or rectally.

[0074] In certain aspects of the methods, the engineered strain of *Saccharomyces* yeast is in a pharmaceutical formulation comprising the engineered strain and a pharmaceutically acceptable carrier or diluent. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[0075] In certain aspects of the methods, the therapeutically-effective amount of the engineered strain of *Saccharomyces* yeast is between 10 ug/kg and 100 mg/kg of the engineered strain per body weight of the subject. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[0076] In certain aspects of the methods, the engineered strain of *Saccharomyces* yeast is administered to the subject orally, nasally or rectally. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[0077] The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described herein, which form the subject of the claims of the invention. It should be appreciated by those skilled in the art that any conception and specific embodiment disclosed herein may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended

claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that any description, figure, example, etc. is provided for the purpose of illustration and description only and is by no means intended to define the limits of the invention.

BRIEF DESCRIPTION OF DRAWINGS

[0078] Figure 1. Illustration of strategies for making binding agents of the invention.

[0079] Figure 2. A diagram of *C. difficile* toxins TcdA and TcdB, showing the glucosyltransferase domains (GT), cysteine protease domains (CPD), translocation domains (TD) and receptor binding domains (RBD) of each toxin. $V_{\text{H}}\text{Hs}$ that recognize and bind the different toxin domains are shown. Those that are underlined are those that have toxin-neutralizing activity.

[0080] Figures 3A-3F. Monomeric or dimeric $V_{\text{H}}\text{Hs}$ possess potent neutralizing activity. $V_{\text{H}}\text{Hs}$ block cell rounding induced by TcdA (Fig. 3A) or TcdB (Fig. 3B) at nM concentrations. (Fig. 3C) Diagram of two heterodimers against TcdA or TcdB. His₍₆₎ tag on N-terminus facilitates purification; a flexible spacer (FS) separate the two $V_{\text{H}}\text{Hs}$. (Fig. 3D) Dimer 5D/E3 increases its neutralizing activity at least 10-fold over a simple mix of the two $V_{\text{H}}\text{Hs}$. Heterodimers fully protected mice from lethal ip challenge with TcdB (Fig. 3E) or TcdA (Fig. 3F).

[0081] Figure 4. Diagram of ABAB. His-tag and E-tag are epitope tags for purification and detection, respectively. FS: flexible linker; ABP: albumin binding peptide.

[0082] Figures 5A-5B. ABAB is highly potent in protecting mice from *C. difficile* spore (Fig. 5A) and toxin (Fig. 5B) challenge. MK HuMabs: a mixture of Merck anti-TcdA (actoxumab) and anti-TcdB (bezlotoxumab) human monoclonal antibodies that are undergoing clinical trials.

[0083] Figures 6A-6B. Anti-toxin sera against both toxins protect mice from CDI. Mice were i.p. injected with 50 ul alpaca anti-sera against TcdA ("Anti-A"), TcdB ("Anti-B"), TcdA + TcdB ("Anti-A + Anti-B") or with 100 ul pre sera or PBS ("CTR") for 4 hours before *C. difficile* spore (UK1 strain, 10^6 spores/mouse) inoculation. Mouse survival (Fig. 6A; Anti-A + Anti-B vs.

PBS, $p = 0.006$) and weight loss (Fig. 6B) are illustrated (*, $p < 0.05$ between Anti-A + Anti-B vs. control).

[0084] Figure 7. The diagram of the ABAB and ABAB-IgG molecules.

[0085] Figures 8A-8B. ELISA analysis of binding of ABAB-IgG to TcdA (Fig. 8A) and TcdB (Fig. 8B) as compared with the binding of the individual VHHs to the respective toxins.

[0086] Figures 9A-9B. Sandwich ELISA analysis of simultaneous binding of the tetraspecific antibody IgG-ABAB to both TcdA and TcdB. Fig. 9A shows serially diluted ABAB-IgG added to ELISA plates coated with TcdA (TxA), followed by TcdB (TxB). Fig. 9B shows serially diluted ABAB-IgG added to ELISA plates coated with TcdB (TxB), followed by TcdA (TxA).

[0087] Figures 10A-10B. ABAB-IgG neutralizing activities against TcdA (Fig. 10A) and TcdB (Fig. 10B).

[0088] Figure 11. Graph showing *in vivo* neutralizing activity of ABAB-IgG against *C. difficile* infection in mice versus Merck antibodies against TcdA and TcdB (actoxumab and bezlotoxumab).

[0089] Figure 12. Design of studies on the effects of prophylactic ABAB-IgG against *C. difficile* infection.

[0090] Figures 13A-13B. Bi-specific sandwich ELISA. (Fig. 13A) A diagram of toxins and antibodies setup in ELISA. (Fig. 13B) O.D. reading of various TcdA concentrations; 125 ng/ml of TcdA was chosen for subsequent ELISA.

[0091] Figures 14A-14B. Activity of ABAB secreted by Sc-ABAB. (Fig. 14A) Neutralizing effect of secreted ABAB in *S. cerevisiae* culture supernatant. Sc: *S. cerevisiae* (BY4741); Sc-ABAB: *S. cerevisiae* (BY4741) – pD1214-FAKS-ABAB; r-ABAB: recombinant ABAB. ABAB in the supernatant of Sc-ABAB is able to fully protect cells from intoxication. ELISA O.D. readings of supernatants from individual Sc-ABAB clones (Fig. 14B).

[0092] Figures 15A-15B. ABAB secretion level with various secretion signals. (Fig. 15A) ABAB secretion measured by ELISA and normalized against cell density based on O.D. 600 in *S. cerevisiae*. Statistical significance was determined by Kruskal-Wallis test followed by Dunn's Multiple comparison test. * $p < 0.05$ ** $p < 0.01$ (Fig. 15B) ABAB secretion measured by ELISA and normalized against cell density based on O.D. 600 in *S. boulardii*. Statistical significance was determined by Mann Whitney test. **** $p < 0.0001$.

[0093] Figure 16. A diagram of targeted deletion of chromosomally encoded genes by homologous recombination in *S. boulardii*.

[0094] Figures 17A-17D. *S. boulardii* *URA3Δ/Δ* expressing ABAB. (Fig. 17A) Growth comparison in YPD containing vancomycin (1mg/ml) versus without. (Fig. 17B) ABAB stability in *S. boulardii* culture supernatant after 2 hours of incubation determined by ELISA. (Fig. 17C) Neutralizing activity of ABAB from the culture supernatant of *S. boulardii* *URA3Δ/Δ* expressing ABAB. (Fig. 17D) ABAB detection in *S. boulardii* *URA3Δ/Δ* expressing ABAB culture supernatant by western blot. Enriched: ABAB contains c-Myc tag at the end of C-terminus and was further concentrated using α -c-Myc tag antibodies.

[0095] Figures 18A-18C. Protection of *S. boulardii* expressing ABAB in CDI prevention in mice. (Fig. 18A) Survival rate, (Fig. 18B) Weight loss, (Fig. 18C) Diarrhea incident, throughout the course of infection were recorded and presented. * significance as determined by Fisher's exact test with two tailed and 95% confidence interval; p value is 0.0108 for Fig. 18A and regular two-way ANOVA (not repeated measures) followed by Dunnett's multiple comparison test was used for Fig. 18B and Fig. 18C, * $P \leq 0.05$. "Sb: EP" is *S. boulardii* with the empty plasmid; "Sb: ABAB" is *S. boulardii* expressing ABAB.

[0096] Figures 19A-19C. Protection of *S. boulardii* expressing ABAB in treating CDI mice. (Fig. 19A) Survival rate, (Fig. 19B) Weight loss, (Fig. 19C) Diarrhea incident, throughout the course of infection were recorded and presented. * significance as determined by Fisher's exact test with two tailed and 95% confidence interval; p value is 0.0256 for Fig. 19A; regular two-way ANOVA (not repeated measures) followed by Dunnett's multiple comparison test for Fig. 19B and Fig. 19C. * $P \leq 0.05$ ** $P \leq 0.01$ **** $P \leq 0.0001$ for Fig. 19B and Fig. 19C. "Sb: EP" is *S. boulardii* with the empty plasmid; "Sb: ABAB" is *S. boulardii* expressing ABAB.

[0097] Figures 20A-20C. Protection of *S. boulardii* expressing ABAB in CDI recurrent mice. (Fig. 20A) Survival rate, (Fig. 20B) Weight loss, (Fig. 20C) Diarrhea incident, throughout the course of infection were recorded and presented. * significance as determined by Fisher's exact test with two tailed and 95% confidence interval; p value is 0.017 for Fig. 20A; regular two-way ANOVA (not repeated measures) followed by Dunnett's multiple comparison test for Fig. 20B and Fig. 20C. * $P \leq 0.05$ *** $P \leq 0.001$ **** $P \leq 0.0001$ for Fig. 20B and Fig. 20C. "Sb: EP" is *S. boulardii* with the empty plasmid; "Sb: ABAB" is *S. boulardii* expressing ABAB.

[0098] Figure 21. A diagram of δ site-targeted chromosomal integration using CRISPR. Ty1-

H3 (Genbank accession no. M18706) was used to blast against draft genome of MYA796 to obtain δ site sequences. Compiled sequences were used to identify common protospacer adjacent motif (PAM) sites and protospacers. Two PAM site sequences were chosen based on best coverage for multiple sites and common homologous sequences located upstream and downstream of the protospacer and PAM sites for simple integration of ABAB expression cassette. PAM site "I" is provided in SEQ ID NO:93; PAM site "II" is provided in SEQ ID NO:94. Homologous recombination sequences used in primers to generate ABAB expression cassette by PCR are underlined.

[0099] Figures 22A-22B. ABAB secretion of *S. boulardii* using CRISPR-based targeting δ site chromosomal integration. (Fig. 22A) ABAB secretion measured by ELISA. ITG: ABAB integration cassette. Low: CRISPR plasmid to ITG ratio at 2; High: CRISPR plasmid to ITG ratio at 0.25. (Fig. 22B) ABAB secretion amount comparison. M^{-/-}^{Cir⁰}:pKC, M^{-/-}^{Cir⁺}:ABAB, M^{-/-}^{Cir⁰}:ABAB are plasmid based. Ch^{Ins}: single site target chromosomal integration of ABAB cassette through conventional homologous recombination. C^{RISPR}1-2: ABAB cassette integration at site I. C^{RISPR}3-4: ABAB cassette integration at site II.

[00100] Figures 23A-23C. Protection of *S. boulardii* expressing ABAB in treating CDI mice. (Fig. 23A) Survival rate, (Fig. 23B) Weight loss, (Fig. 23C) Diarrhea incident, throughout the course of infection were recorded and presented. * significance as determined by Fisher's exact test with two tailed and 95% confidence interval; p value is 0.0325 for (Fig. 23A); regular two-way ANOVA (not repeated measures) followed by Dunnett's multiple comparison test for Fig. 23B and Fig. 23C. * P \leq 0.05 ** P \leq 0.01 for Fig. 23B and Fig. 23C.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

[00101] Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found, for example, in Benjamin Lewin, *Genes VII*, published by Oxford University Press, 2000 (ISBN 019879276X); Kendrew et al. (eds.); *The Encyclopedia of Molecular Biology*, published by Blackwell Publishers, 1994 (ISBN 0632021829); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by Wiley, John & Sons, Inc., 1995 (ISBN 0471186341); and other similar technical references.

[00102] As used herein, “a” or “an” may mean one or more. As used herein when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more. Furthermore, unless otherwise required by context, singular terms include pluralities and plural terms include the singular.

[00103] As used herein, “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term “about” generally refers to a range of numerical values (e.g., +/- 5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.

II. *The Present Invention*

[00104] *C. difficile*-associated disease (CDI) is mainly caused by two large exotoxins, namely toxin A (TcdA) and toxin B (TcdB), produced by the bacteria. These toxins are structurally similar, large, single-chain proteins (TcdA is about 300kD; TcdB is about 270kD) that exhibit similar modes of action on host cells. Both toxins target host Rho GTPases, leading to enzyme inactivation, followed by cytoskeleton disorganization and apoptosis. In intestinal epithelial cells, TcdA catalyzes glucosylation of the Rho GTPases, leading to reorganization of the actin cytoskeleton with accompanying morphological changes such as complete rounding of cells and destruction of the intestinal barrier function. The toxins can individually cause CDI in animals, and TcdA⁻ TcdB⁻ strains of the bacteria are avirulent.

[00105] Numerous independent studies have demonstrated that neutralizing antibodies against the toxins confer protection against CDI [24-33]. Because TcdA and TcdB are essential virulence factors for *C. difficile*, neutralizing antibodies produced against both toxins protect against toxigenic *C. difficile* infection in animal models [30-33]. In humans, high serum levels of antitoxin antibodies are associated with reduced disease severity and incidence of relapse [9,25,29].

[00106] Therefore, a preventative rationale for systemically and orally administered antitoxin antibodies exists. However, monoclonal antibodies targeting a single epitope are typically low affinity, and use of such antibodies runs the risk of inducing mutations within the epitopes of the

toxins thereby creating additional strains. Thus, neutralizing antitoxins targeting multiple, key, and conserved toxin epitopes are highly desirable.

[00107] The present invention builds on existing knowledge regarding anti-TcdA and anti-TcdB antibodies for the treatment and prevention of CDI, and the symptoms of CDI. Provided herein are antibody-based, fusion protein binding agents derived from human and camelid immunoglobulins, optionally expressed by the probiotic yeast *Saccharomyces* strain in a subject. These binding agents recognize and bind with specificity to *C. difficile* TcdA and/or TcdB. Some of these binding agents exhibit toxin-neutralizing activity. These yeast-based immunotherapeutic can be used to treat or prevent primary and recurrent CDI, as well as the symptoms of primary and recurrent CDI. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[00108] As discussed in detail below, camelid animals (dromedary camels, Bactrian camels, wild Bactrian camels, llamas, alpacas, vicuñas, and guanacos) produce a class of functional immunoglobulins that lack light chains and are thus heavy chain-only antibodies (HCAbs) [34] with binding properties equivalent to those achieved by conventional IgG [35]. The V_H domain of HCAbs, called V_{HH} , is similar to the conventional human V_H domain but has unique sequence and structural characteristics [36]. DNA encoding this domain can be readily cloned and expressed in microbes to yield soluble protein monomers that retain the antigen-binding properties of the parent HCAb. These V_{HH} peptide monomer binding agents are small (~15 kDa), easy to produce, and generally more stable than conventional antibody fragments [37-39]. V_{HH} s have being explored to treat intestinal diseases since they are relatively resistant to proteases and can be further engineered to enhance such properties [40]. They can also be produced as fusion proteins with human antibodies, such as IgG, and fragments of human antibodies, such as Fc domains.

[00109] The present invention utilizes the advantageous characteristics of HCAbs in the production of binding agents that can be used in the treatment and prevention of CDI. As disclosed herein, V_{HH} peptide monomers were screened for TcdA and TcdB epitope recognition and binding. Those monomers that exhibited epitope binding and had toxin-neutralizing activity were linked to produce the binding agents of the invention. The binding agents include simple V_{HH} peptide monomers and linked groups of V_{HH} peptide monomers (comprising 2, 3, 4, or more monomers), as well as more complex binding agents that comprise V_{HH} peptide monomers

joined to antibody Fc domains, as well as V_HH peptide monomers joined to IgG antibodies (see Figure 1).

[00110] Further, *Saccharomyces boulardii*, a Generally Regarded as Safe (GRAS) organism by the FDA, is commonly available over-the-counter for use in promoting intestinal health and amelioration of gastrointestinal illness due to diarrheal diseases. This yeast strain has been studied in multiple randomized double-blinded placebo-controlled clinical trials for both safety and efficacy against intestinal diseases including CDI [42-46]. *S. boulardii* treatment significantly reduced CDI recurrence [44-46], and those recurrent patients had significantly less *S. boulardii* in stools than non-recurring patients [43]. The immune modulatory effects of *S. boulardii* that provide protection against *C. difficile* toxin-induced inflammation have been described [47-49]. In addition, *S. boulardii* may help in maintaining normal microbiota [50]; a recent clinical trial (NCT01473368) found that *S. boulardii* treatment can prevent some antibiotic-induced microbiome changes and, in parallel, can reduce antibiotic-associated diarrhea.

[00111] *S. cerevisiae* (commonly known as “brewer’s yeast”), which is genetically related to *S. boulardii*, has been used successfully to express V_HHs with high yield [51]. *S. boulardii* is physiologically distinct from *S. cerevisiae*, although genome analysis has revealed that both genomes are remarkably similar at the nucleotide level [52,53]. Therefore, molecular genetic tools previously developed for use in *S. cerevisiae* are now being used with *S. boulardii* [54-56], making this probiotic a candidate for engineering as a therapeutic agent against CDI.

[00112] There are several additional metabolic characteristics which make *S. boulardii* ideal for use as an oral therapeutic agent. In contrast to *S. cerevisiae*, *S. boulardii* grows well at 37°C and it is more resistant to acidic environmental conditions [57], making this strain particularly well suited for better surviving and persisting in the human intestinal tract after oral administration. In addition, an experimental murine oral colonization model with *Saccharomyces* is well characterized [58]; using this model, protection has been reported against oral challenge with enteric pathogens such as *Salmonella* Typhimurium [58,59] and Enteritidis [60] in conventional mice orally treated with *S. boulardii*, as well as protection against CDI challenge in pretreated gnotobiotic animals [58,61]. The probiotic *S. boulardii*, genetically engineered to secrete V_HH binding agents capable of neutralizing both TcdA and TcdB of *C. difficile*, could

significantly improve the therapeutic capacity of this probiotic to disrupt both ongoing and recurrent CDI.

[00113] In view of the exceptional characteristics of *S. boulardii*, strains of *S. boulardii* expressing the binding agents defined herein were produced and tested. As described in the Examples, these yeast-based immunotherapeutics can be used to treat or prevent primary and recurrent CDI, as well as the symptoms of primary and recurrent CDI.

V_HH monomers & V_HH heterodimers

[00114] As initially reported in WO 16/127104, the inventors established an efficient platform to screen V_HH monomers against specific domains of both *C. difficile* toxins. Using highly immunogenic atoxic holotoxins for immunization, and bioactive chimeric toxins (with normal domain functions) for screening, panels of V_HH monomers binding to different domains of TcdA or TcdB were prepared. A majority of these V_HH monomers possessed potent neutralizing activity and their binding to specific domains of TcdA and TcdB was determined (Fig. 2).

[00115] Several of the V_HH monomers bind to highly conserved TcdA/TcdB epitopes. For example, the E3 V_HH monomer binds to the Rho GTPase binding site and blocks glucosylation; the AH3 V_HH monomer binds to the GT domain of the toxin; the 7F V_HH monomer binds to cysteine protease cleavage sites and blocks GT domain cleavage and release. Some V_HH monomers have potent toxin neutralizing activity, capable of blocking toxin cytotoxic activity at nM concentrations (monomers underlined in Fig. 2; see also Figs. 3A and 3B). Table 1 references amino and nucleic acid sequences in the Sequence Listing for some of these V_HH peptide monomers, both wild-type and codon-optimized versions. While both the optimized and non-optimized versions can be used in the production of the various binding agents of the present invention, the codon-optimized versions are preferred for expression in mammalian cells.

[00116] The present invention includes each of the V_HH peptide monomers referenced in Table 1 as well as sequence variants thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the peptide sequence and retaining the toxin binding and/or neutralizing activity of the wild-type peptide. The present invention also includes polynucleotide sequences encoding each of the V_HH peptide monomers of Table 1 and the sequence variants thereof, as well as complementary strands thereof.

Table 1

Name	Codon Optimized?	Location of epitope	SEQ ID NO for Amino Acid Seq.	SEQ ID NO for Nucleic Acid Seq.
5D	Yes	TcdB glucosyltransferase domain	1	2
E3	Yes	TcdB glucosyltransferase domain	3	4
AA6	Yes	TcdA cysteine protease domain	5	6
AH3	Yes	TcdA glucosyltransferase domain	7	8
5D	No	TcdB glucosyltransferase domain	48	49
E3	No	TcdB glucosyltransferase domain	50	51
AA6	No	TcdA cysteine protease domain	52	53
AH3	No	TcdA glucosyltransferase domain	54	55

[00117] To enhance the binding activity of the peptide monomers, V_HH peptide homo- and hetero-dimer binding agents were created, where two V_HH peptide monomers are linked (Fig. 3C). Homodimer binding agents comprise two identical monomers that bind identical epitopes on two different toxins. Heterodimer binding agents comprise two different monomers that bind two distinct epitopes of the same toxin or distinct epitopes on two different toxins. The V_HH heterodimers were found to possess substantially enhanced neutralizing activities compared with equimolar mixtures of the individual V_HH peptide monomers comprising the heterodimers (Fig. 3D). Indeed, heterodimers 5D/E3 and AH3/AA6 were found to fully protect mice from lethal systemic TcdB or TcdA challenge respectively, whereas mixed 5D and E3, or AA6 alone were only partially protective (Figs. 3E and 3F).

[00118] The V_HH monomers in the homo- and hetero-dimers are linked using a short, flexible linker of between 10 and 20 amino acids. Suitable linkers include those provided in Table 2. Table 2 also includes codon-optimized versions of the three linkers. While both the optimized and non-optimized versions can be used in the production of the various binding agents of the present invention, the codon-optimized versions are preferred for expression in mammalian cells.

Table 2

Name	Codon Optimized?	SEQ ID NO for Amino Acid Seq.	SEQ ID NO for Nucleic Acid Seq.
Linker -1	Yes	9	10
Linker -2	Yes	11	12
Linker -3	Yes	13	14
Linker -1	No	56	57
Linker -2	No	58	59
Linker -3	No	60	61

It will be understood by the skilled artisan that minor changes can be made to the sequence of the flexible linker without departing from the properties of the peptide. Sequence variants of the flexible linker having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the peptide sequence and retaining properties of the linker upon which they are based may thus be used.

[00119] The present invention includes V_HH peptide homodimer binding agents comprising pairs of any of the monomers listed in Table 1, linked by a flexible linker as defined above. The present invention also includes V_HH peptide heterodimer binding agents comprising any combination of two of the monomers listed in Table 1, linked by a flexible linker as defined above. Exemplary heterodimers are provided in Table 3.

Table 3

Name	SEQ ID NO for Amino Acid Seq.	SEQ ID NO for Nucleic Acid Seq.
AH3-5D	15	16
AA6-E3	17	18
5D-E3	62	63
AH3-AA6	64	65

[00120] The present invention also includes sequence variants of the V_HH peptide homo- and hetero-dimers having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the protein sequence and retaining the toxin binding and/or neutralizing activity of the wild-type protein. The present

invention further includes polynucleotide sequences encoding each the V_HH peptide homo- hetero-dimers and the sequence variants thereof, as well as complementary strands thereof.

[00121] The invention also includes V_HH peptide homo- and hetero-trimer binding agents where three monomers are linked using the flexible linkers defined above in Table 2. Any combination of the monomers of Table 1 may be used, including trimers comprising three copies of the same monomer, trimers comprising two copies of one monomer and a single copy of another, and trimers comprising three different monomers. Sequence variants of the V_HH peptide homo- and hetero-trimers are included in the invention, having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the protein sequence and retaining the toxin binding and/or neutralizing activity of the wild-type protein. The present invention further includes polynucleotide sequences encoding each the V_HH peptide homo- and hetero-trimers and the sequence variants thereof, as well as complementary strands thereof.

ABAB

[00122] The success of the peptide monomers and heterodimers allowed the inventors to develop binding agents comprising four linked V_HH peptide monomers. This was a goal of the research as earlier work had shown that the most useful agents in the treatment and prevention of CDI would be single antibodies that can simultaneously neutralize both TcdA and TcdB as this would be necessary in order to convey full protection against most pathogenic *C. difficile* strains. By creating tetra-specific binding agents that recognize and bind two epitopes on each of the toxins, the binding and neutralizing activity of the proteins might be strengthened. Therefore, four domain (tetra-specific) V_HH binding agents were generated.

[00123] The tetra-specific, tetrameric binding agents can be prepared from any combination of the monomers of Table 1, where the monomers are linked using the flexible linkers of Table 2. These binding agents include those having four copies of the same monomer, those having three copies of the same monomer, those having two copies of the same monomer, those having four unique monomers, and variations therein. Sequence variants of the tetramers are included in the invention, having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the protein sequence and retaining the toxin binding and/or neutralizing activity of the wild-type protein. The present invention

further includes polynucleotide sequences encoding each tetramer and the sequence variants thereof, as well as complementary strands thereof.

[00124] ABBA is a particular binding agent of the invention that comprises four linked V_HH monomers, AH3-E3-E3-AA6. ABBA thus has two identical monomers (E3) and two additional different monomers (AH3 and AA6) (See Table 1).

[00125] ABAB is another particular binding agent of the invention that comprises four linked V_HH monomers, each of which has binding specificity for a different epitope of TcdA or TcdB. ABAB is thus a tetra-specific, tetrameric binding agent that consists of four distinct neutralizing V_HH monomers, two against TcdA and two against TcdB. This structural feature allows ABAB to bind simultaneously to two distinct neutralizing epitopes on each toxin. As described below, affinity/avidity and neutralizing activity of ABAB is more than 3-logs higher than human monoclonal antibodies (HuMabs) currently undergoing clinical trials for treatment of CDI.

[00126] ABAB binding agent was prepared by linking V_HH monomers AH3, 5D, AA6, and E3 (Table 1) using flexible linkers (Table 2). This binding agent targets conserved, non-overlapping epitopes and has excellent toxin neutralizing activity. In the design of ABAB (Fig. 4), V_HH peptide monomers AH3 and AA6 were separated by placing the 5D between them because AH3 and AA6 bind to GT and TD respectively (Fig. 2), which are spatially distant to each other. This design allowed AH3 and AA6 to bind to TcdA simultaneously.

[00127] The complete amino acid sequence comprising ABAB is provided in SEQ ID NO:19; the nucleic acid sequence encoding the protein is provided in SEQ ID NO:20. The present invention thus includes the ABAB binding agent provided in SEQ ID NO:19, as well as sequence variants of the ABAB binding agent having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the protein sequence and retaining the toxin binding and/or neutralizing activity of the wild-type protein. The sequence variants include variants wherein the variant is humanized and/or wherein the amino acids are optimized for production and secretion by yeast.

[00128] The present invention further includes polynucleotide sequences encoding the ABAB binding agent (e.g., SEQ ID NO:20) and the sequence variants thereof, as well as complementary strands thereof.

[00129] Modified versions of the ABAB binding agent encompassed by the invention includes those having one or more of (i) a His₍₆₎-tag (HHHHHH; SEQ ID NO:66) at the amino

terminus of the protein to aid in purification, (ii) an E-tag (GAPVPYPDPLEPR; SEQ ID NO:67) at the carboxy terminus of the protein to aid in detection; (iii) an albumin-binding peptide (ABP) (DICLPRWGCLWD; SEQ ID NO:21) at the carboxyl end of the construct to increase serum half-life of the protein as V_HH monomers have a half-life of 2-3 hr and inclusion of ABP can increase the serum half-life to 10 hr (see Fig. 4); and a D7 tag (SSAPTKAKRRVVQREKT; SEQ ID NO:112) at the carboxy terminus of the protein. The invention includes versions of the ABAB binding agent having one, two, three or four of these tags and peptides. An exemplary modified ABAB binding agent that includes the His tag and the D7 tag comprises the amino acid sequence set forth in SEQ ID NO:113 (the coding sequence is set forth in SEQ ID NO:114).

[00130] When yeast strains are engineered to produce ABAB, the protein can be also modified to include a secretion signal at the amino terminus of the protein. The secretion signal may be, but is not limited to, one of the sequences shown in Table 4.

Table 4 – Secretion sequences for protein secretion in yeast

Secretion signal	Amino acid sequence	Abbr.
α -factor_full (<i>S. cerevisiae</i>)	MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGY SDLEGDFDVAVLPFSNSTNNGLLFINTTASIAAKEEGVSL EKREAEA (SEQ ID NO:96)	FAKS
α -factor_T_kex_ste (<i>S. cerevisiae</i>)	MRFPSIFTAVLFAASSALAAPVNTTTEDELEGGDFDVAVLP FSASIAAKEEGVSLEKREAEA (SEQ ID NO:97)	AKS
α -factor_T_kex (<i>S. cerevisiae</i>)	MRFPSIFTAVLFAASSALAAPVNTTTEDELEGGDFDVAVLP FSASIAAKEEGVSLEKR (SEQ ID NO:98)	AK
α -factor_T (<i>S. cerevisiae</i>)	MRFPSIFTAVLFAASSALA (SEQ ID NO:99)	AT
Alpha-amylase (<i>Aspergillus niger</i>)	MVAWWSLFLYGLQVAAPALA (SEQ ID NO:100)	AA
Glucoamylase (<i>Aspergillus awamori</i>)	MSFRSLLALSGLVCSGLA (SEQ ID NO:101)	GA
Inulinase (<i>Kluyveromyces maxianus</i>)	MKLAYSLLLPLAGVSA (SEQ ID NO:102)	IN
Invertase (<i>S. cerevisiae</i>)	MLLQAFLFLLAGFAAKISA (SEQ ID NO:103)	IVS
Killer protein (<i>S. cerevisiae</i>)	MTKPTQVLVRSVSILFFITLLHLVVA (SEQ ID NO:104)	KP
Lysozyme (<i>Gallus gallus</i>)	MLGKNPDMCLVLVLLGLTALLGICQG (SEQ ID NO:105)	LZ
Serum albumin (<i>Homo sapiens</i>)	MKWVTFISLLFLFSSAYS (SEQ ID NO:106)	SA

[00131] Exemplary modified ABAB binding agents that include an amino-terminal secretion signal include AT-ABAB and IVS-ABAB.

[00132] An exemplary modified ABAB binding agent that is expressed from a plasmid in yeast or bacteria includes the ABAB binding agent set forth in SEQ ID NO:107, which is encoded by the polynucleotide sequence set forth in SEQ ID NO:108.

[00133] An exemplary modified ABAB binding agent that is expressed in yeast after chromosomal integration includes the ABAB binding agent set forth in SEQ ID NO:109, which is encoded by the polynucleotide sequence set forth in SEQ ID NO:110.

[00134] Each of the binding agents of the invention binds to TcdA and/or TcdB with specificity. In certain aspects of the invention, the binding agents exhibit TcdA and/or TcdB neutralizing activity.

[00135] For the sake of clarity it can be noted that as used herein, “mono-specific”, “bi-specific”, “tri-specific”, “tetra-specific”, etc., mean the particular binding agent binds to 1, 2, 3, 4, etc., different epitopes, respectively. As used herein, “monomeric”, “dimeric”, “trimeric”, “tetrameric”, etc., mean that the particular binding agent has 1, 2, 3, 4, etc., separate V_HH peptide monomers that bind to the epitopes, respectively. Thus, a mono-specific, dimeric binding agent would display two V_HH peptide monomers that bind to the same epitope (e.g., a homodimer), and a bi-specific, dimeric binding agent would have two V_HH peptide monomers that bind to two different epitopes (e.g., a heterodimer). A tetra-specific, octameric binding agent has eight V_HH peptide monomers that recognize four different epitopes.

V_HH-Fc

[00136] It is well known that chimeric Fc-fusion proteins have the potential of increasing the half-life of a protein *in vivo*. This strategy has been applied in several FDA approved drugs, such as Etanercept. A proof-of principle study has shown that single-chain antibodies can be correctly assembled and expressed by B cells of transgenic mice carrying a mini-Ig construct encoding a dromedary V_HH and the Fc domain of human IgG. Also EG2-Fc, a chimeric anti-EGFR/EGFR_{vIII} V_HH, exhibited excellent tumor accumulation *in vivo* and has pharmacokinetic properties that could improve glioblastoma targeting.

[00137] The present invention includes binding agents comprising V_HH peptide monomers joined to antibody Fc domains (V_HH-Fc), where the binding agents bind TcdA and/or TcdB. In these Fc domain-based binding agents, one, two, three, four or more of the V_HH peptide monomers are joined to the hinge, C_H2 and C_H3 regions of the Fc domain of an antibody heavy chain. Thus, the peptide monomers replace the Fab regions of the antibody.

[00138] The V_HH peptide monomers may be any of those provided in Table 1 above and include 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5) and AH3 (SEQ ID NO:7) V_HH peptide monomers. Where two or more monomers are linked, the monomers may be linked by flexible peptide linkers, generally comprising between 10 and 20 amino acids. Suitable linkers include those linkers provided in Table 2, such as linker-1 (SEQ ID NO:9), linker-2 (SEQ ID NO:11), and linker-3 (SEQ ID NO:13).

[00139] While the V_HH-Fc will typically be composed of two identical chains that self-assemble intracellularly after production, the invention also includes V_HH-Fc binding agents comprising two different Fc chains. In such circumstances, the sequence of the V_HH monomer(s) alone may differ between the two Fc chains, or the Fc chains themselves may differ in sequence, or both the V_HH monomer(s) and the Fc chains may differ in sequence.

[00140] One type of V_HH-Fc binding agent is an octameric binding agent comprising an antibody Fc domain and first, second, third and fourth V_HH peptide monomers, where the V_HH peptide monomers have binding specificity for an epitope of TcdA or toxin B TcdB, where the first, second, third and fourth V_HH peptide monomers are linked together and joined to amino termini of both antibody Fc domains, and where the antibody Fc domain comprises the hinge, C_H2 and C_H3 regions of an antibody heavy chain. Because this binding agent has four V_HH peptide monomers, it can be mono-specific (where all of the monomers bind the same epitope), bi-specific (where the monomers bind two different epitopes), tri-specific (where the monomers bind three different epitopes), or tetra-specific (where the monomers bind four different epitopes).

[00141] A specific example of a tetra-specific V_HH-Fc binding agent is the ABAB-Fc binding agent, a tetra-specific, octameric binding agent comprising an antibody Fc domain and two sets of linked first, second, third and fourth V_HH peptide monomers, wherein the antibody Fc domain comprises two arms, each arm comprising hinge, C_H2 and C_H3 regions of an antibody heavy chain, and each arm having an amino terminus, wherein for each arm of the Fc domain, one set

of linked first, second, third and fourth V_HH peptide monomers is joined to the amino terminus of the arm, and where the V_HH peptide monomers have binding specificity for an epitope of TcdA or TcdB (see Fig. 1). This binding agent is termed “tetra-specific” as it recognizes four different toxin epitopes. It is termed “octameric” as it bears eight V_HH peptide monomers (two copies of the first monomer, two copies of the second monomer, two copies of the third monomer, and two copies of the fourth monomer). ABAB-Fc was found to exhibit specific binding and neutralizing activity.

[00142] The ABAB-Fc binding agent was prepared by generating an expression vector encoding the V_HH peptide monomers AH3/5D/AA6/E3 (linked in the noted order) joined to a human IgG1 Fc domain. The V_HH peptide monomers were separated by flexible linkers of Table 2. The nucleic acid sequence encoding each chain is provided in SEQ ID NO:23. The amino acid sequence of each chain is provided in SEQ ID NO:22. Upon self-assembly of pairs of the chains after expression, the tetra-specific, octameric binding agent resulted. The invention includes the ABAB-Fc binding agent of SEQ ID NO:22, modified versions of ABAB binding agents as defined above, and sequence variants thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the protein sequence and retaining the toxin binding and/or neutralizing activity of the wild-type protein. The present invention further includes polynucleotide sequences encoding these sequence variants and complementary strands thereof.

[00143] Mono-specific V_HH-Fc binding agents (AH3-Fc, 5D-Fc, E3-Fc, AA6-Fc) and bi-specific V_HH-Fc binding agents (e.g., AH3/5D-Fc and AA6/E3-Fc) were also made using this Fc-fusion system. With respect to mono-specific binding agents, single V_HH peptide monomers were joined to human IgG1 Fc domains. Upon expression and assembly, pairs of the chains resulted in mono-specific, dimeric binding agents (when the chains were identical) or bi-specific, dimeric binding agents (when the chains were different). With respect to bi-specific binding agents, two linked V_HH peptide monomers (V_HH homo- or hetero-dimers) were joined to human IgG1 Fc domains. Upon expression and assembly, pairs of the chains resulted in bi-specific, tetrameric binding agents (when the chains were identical) or tetra-specific, tetrameric binding agents (when the chains were different). Table 5 provides the sequences for some these binding agents.

Table 5

Name	SEQ ID NO for Amino Acid Seq.	SEQ ID NO for Nucleic Acid Seq.
5D-Fc	24	25
E3-Fc	26	27
AA6-Fc	28	29
AH3-Fc	30	31
AH3-5D-Fc	32	33
AA6-E3-Fc	34	35

Specific pairings with one monomer include: 5D-Fc + 5D-Fc; E3-Fc + E3-Fc; AA6-Fc + AA6-Fc; AH3-Fc + AH3-Fc; 5D-Fc + E3-Fc; 5D-Fc + AA6-Fc; 5D-Fc + AH3-Fc; E3-Fc + AA6-Fc; E3-Fc + AH3-Fc; and AA6-Fc + AH3-Fc. Specific pairings with two monomers include: AH3-5D-Fc + AH3-5D-Fc; AA6-E3-Fc + AA6-E3-Fc; and AH3-5D-Fc + AA6-E3-Fc.

[00144] Bi-specific, tetrameric V_HH-Fc binding agents were produced comprising an antibody Fc domain and two sets of linked first and second V_HH peptide monomers, wherein the antibody Fc domain comprises two arms, each arm comprising hinge, C_H2 and C_H3 regions of an antibody heavy chain, and each arm having an amino terminus, wherein for each arm of the Fc domain, one set of linked first and second V_HH peptide monomers is joined to the amino terminus of the arm, and where the V_HH peptide monomers have binding specificity for an epitope of TcdA or TcdB. This binding agent is termed “bi-specific” as it recognizes two different toxin epitopes. It is termed “tetrameric” as it bears four V_HH peptide monomers (two copies of the first monomer, and two copies of the second monomer). The first and second V_HH peptide monomers may have binding specificity for the same or different epitopes. The V_HH peptide monomers may independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[00145] A specific example of a bi-specific, tetrameric V_HH-Fc binding agent comprises the amino acid sequence set forth in SEQ ID NO:32 (AH3/5D-Fc). The invention also includes sequence variants thereof having at least 95% sequence identity, where the sequence variant retains toxin-neutralizing activity. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[00146] A specific example of a bi-specific, tetrameric V_HH-Fc binding agent comprises the amino acid sequence set forth in SEQ ID NO:34 (AA6/E3-Fc). The invention also includes sequence variants thereof having at least 95% sequence identity, where the sequence variant retains toxin-neutralizing activity. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[00147] The V_HH-Fc binding agents bind to TcdA and/or TcdB with specificity. In certain aspects of the invention, the binding agents exhibit TcdA and/or TcdB neutralizing activity.

V_HH-IgG

[00148] The present invention also includes binding agents comprising V_HH peptide monomers joined to more of an antibody than the Fc domain alone. V_HH-IgG binding agents comprise one, two, three, four or more of the V_HH peptide monomers are joined to the light (kappa or lambda) and heavy chains of an IgG antibody lacking the variable regions of the antibody. Thus, the peptide monomers replace the variable regions of the antibody.

[00149] The V_HH peptide monomers may be any of those provided in Table 1 above and include 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5) and AH3 (SEQ ID NO:7) V_HH peptide monomers. Where two or more monomers are linked, the monomers may be linked by flexible peptide linkers, generally comprising between 10 and 20 amino acids. Suitable linkers include those linkers provided in Table 2, such as linker-1 (SEQ ID NO:9), linker-2 (SEQ ID NO:11), and linker-3 (SEQ ID NO:13).

[00150] V_HH-IgG binding agents include octameric binding agents comprising an IgG antibody and first, second, third and fourth V_HH peptide monomers, wherein the V_HH peptide monomers have binding specificity for an epitope of TcdA or TcdB, wherein first and second V_HH peptide monomers are linked together and joined to amino termini of both light chains of the antibody, wherein the light chains lack the antibody variable regions, and wherein third and fourth V_HH peptide monomers are linked together and joined to amino termini of both heavy chains of the antibody, wherein the heavy chains lack the antibody variable regions. Because this binding agent has four V_HH peptide monomers, it can be mono-specific (where all of the monomers bind the same epitope), bi-specific (where the monomers bind two different epitopes), tri-specific (where the monomers bind three different epitopes), or tetra-specific (where the monomers bind four different epitopes).

[00151] A specific example of a tetra-specific V_HH-IgG binding agent is the ABAB-IgG binding agent, a tetra-specific, octameric binding agent comprising an IgG antibody, two sets of linked first and second V_HH peptide monomers, and two sets of linked third and fourth V_HH peptide monomers, wherein the IgG antibody comprises two arms, each arm comprising a heavy chain lacking a variable region and a light chain lacking a variable region, and each chain having an amino terminus, wherein for each arm of the antibody, one set of linked first and second V_HH peptide monomers is joined to the amino terminus of the light chain, and one set of linked third and fourth V_HH peptide monomers is joined to the amino terminus of the heavy chain, and wherein the V_HH peptide monomers have binding specificity for an epitope of TcdA or TcdB (see Fig. 1). This binding agent is termed “tetra-specific” as it recognizes four different toxin epitopes. It is termed “octameric” as it bears eight V_HH peptide monomers (two copies of the first monomer, two copies of the second monomer, two copies of the third monomer, and two copies of the fourth monomer). In certain aspects, the first, second, third and fourth V_HH peptide monomers may each have binding specificity for a different epitope. In certain aspects, two of the V_HH peptide monomers may have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers may have binding specificity for epitopes of TcdB. In certain aspects, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[00152] A specific example of a tetra-specific, octameric ABAB-IgG binding agent comprises a light (kappa) chain having the amino acid sequence set forth in SEQ ID NO:46 (AA6/E3 kappa) or a sequence variant having at least 95% sequence identity thereto, and a heavy chain having the amino acid sequence set forth in SEQ ID NO:44 (AH3/5D heavy) or a sequence variant having at least 95% sequence identity thereto. In this aspect, the sequence variants retain toxin-neutralizing activity. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers. This binding agent was produced by preparing two separate expression vectors, the first encoding the V_HH peptide monomers AH3/5D (linked in the noted order) joined to the human IgG1 antibody heavy chain lacking the variable region and the second encoding the V_HH peptide monomers AA6/E3 (linked in the noted order) joined to the human IgG1 antibody light (kappa) chain lacking the variable region. The nucleotide sequence encoding the AA6/E3-IgG1 light (kappa) chain is provided in SEQ ID

NO:47. The nucleotide sequence encoding the AH3/5D-IgG1 heavy chain is provided in SEQ ID NO:45. The invention includes sequence variants of ABAB-IgG having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity over the entire length of the protein sequence and retaining the toxin binding and/or neutralizing activity of the wild-type protein. The present invention further includes polynucleotide sequences encoding these sequence variants and complementary strands thereof.

[00153] Bi-specific or tetra-specific, tetrameric IgG binding agents are included in the invention. Such binding agents comprise an IgG antibody and first, second, third and fourth V_HH peptide monomers, wherein the IgG antibody comprises two arms, each arm comprising a heavy chain lacking a variable region and a light chain lacking a variable region, and each chain having an amino terminus, wherein for a first arm of the antibody, the first V_HH peptide monomer is joined to the amino terminus of the light chain, and the second V_HH peptide monomer is joined to the amino terminus of the heavy chain, wherein for a second arm of the antibody, the third V_HH peptide monomer is joined to the amino terminus of the light chain, and the fourth V_HH peptide monomer is joined to the amino terminus of the heavy chain, and where the V_HH peptide monomers have binding specificity for an epitope of TcdA or TcdB. When the binding agent is “tetra-specific”, it recognizes four different toxin epitopes; when “bi-specific” it recognizes two different toxin epitopes. The binding agents “tetrameric” as they bear four V_HH peptide monomers (when bi-specific, the first and second monomer have the same sequence and bind the same epitope, and the third and fourth monomers have the same sequence and bind the same epitope; when tetra-specific, each of the monomers has a different sequence and binds a different epitope).

[00154] When the binding agent is bi-specific, the first and third monomers have binding specificity for different epitopes, the first and second monomers have identical amino acid sequences, and the third and fourth monomers have identical amino acid sequences. In certain aspects, one of the V_HH peptide monomers has binding specificity for an epitope of TcdA and one of the V_HH peptide monomers has binding specificity for an epitope of TcdB.

[00155] When the binding agent is tetra-specific, each of the V_HH peptide monomers has binding specificity for a different epitope. In certain aspects, two of the V_HH peptide monomers have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers have binding specificity for epitopes of TcdB.

[00156] In certain aspects, each of the V_HH peptide monomers has binding specificity for epitopes of TcdA. In other aspects, each of the V_HH peptide monomers has binding specificity for epitopes of TcdB.

[00157] In certain aspects, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.

[00158] A specific example of a bi-specific, tetrameric IgG binding agent comprises a light (kappa) chain having the amino acid sequence set forth in SEQ ID NO:40 (AA6 kappa) and a heavy chain having the amino acid sequence set forth in SEQ ID NO:36 (AH3 heavy). The invention also includes sequence variants thereof having at least 95% sequence identity, where the sequence variant retains toxin neutralizing activity. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[00159] Another specific example of a bi-specific, tetrameric IgG binding agent comprises a light (kappa) chain having the amino acid sequence set forth in SEQ ID NO:42 (E3 kappa) and a heavy chain having the amino acid sequence set forth in SEQ ID NO:38 (5D heavy). The invention also includes sequence variants thereof having at least 95% sequence identity, where the sequence variant retains toxin neutralizing activity. The variant amino acids of the sequence variant may be located in framework regions of the V_HH peptide monomers.

[00160] Table 6 provides the sequences used to generate bi- and tetra-specific V_HH-IgG binding agents. Other suitable pairings include (i) 5D-IgG1-heavy chain + AA6-light (kappa or lambda) chain, and (ii) AH3-IgG1-heavy chain + E3-light (kappa or lambda) chain.

Table 6

Name	SEQ ID NO for Amino Acid Seq.	SEQ ID NO for Nucleic Acid Seq.
AH3-IgG1 heavy chain	36	37
5D-IgG1 heavy chain	38	39
AA6-IgG1 light (kappa) chain	40	41
E3-IgG1 light (kappa) chain	42	43
AH3/5D-IgG1 heavy chain	44	45
AA6/E3-IgG light (kappa) chain	46	47

However, the present invention includes IgG1 heavy chains joined to any of AH3, 5D, AA6 and E3, and IgG1 light (kappa or lambda) chains joined to any of AH3, 5D, AA6 and E3. Further, all possible combinations of the heavy and light (kappa or lambda) chains are encompassed herein.

Humanized Binding Agents

[00161] Due to their small size and the high degree of identity of their framework to the human V_H framework of family III, V_HH peptide monomers are expected to exhibit low immunogenicity when administered to humans. While the systemic application of small monovalent V_HH monomers seems to induce little, if any, neutralizing antibody responses, protein immunogenicity generally increases with size and complexity. Two major hurdles for repeated and/or long-term *in vivo* use of V_HH monomers are their likely short half-life and potential immunogenicity. To increase the valence and circulating half-life, V_HH monomers can be fused with human IgG and Fc domains as discussed herein. To address possible immunogenicity, the V_HH monomers can be humanized as needed without compromising their expression level, affinity, solubility, and stability. These strategies should result in good expression, stability, and solubility of humanized V_HH monomers (*hV_HH* monomers), while retaining the antigen specificity and affinity of the loop donor V_HH .

[00162] *hV_HH* monomers that gain highest identity to human V_H gene(s) and possess the highest binding/neutralizing activity are selected, after which they are transferred into the V_HH -multimers (e.g., ABAB), V_HH -Fc and V_HH -IgG constructs to generate fully humanized binding agents, such as fully humanized ABAB, ABAB-IgG and ABAB-Fc binding agents. The protein sequences of these humanized binding agents can be essentially identical to that of a human antibody variant, despite the non-human origin of some of its CDR segments that are responsible for the ability of the antibody to bind to its target antigen. Therefore, this strategy decreases the chance for potential immunogenicity *in vivo* and thus increase their safety and half-life *in vivo*.

[00163] The binding agents of the present invention thus encompasses humanized versions of each of the binding agents defined herein, comprising *hV_HH* peptide monomers.

Epitope Binding Fragments

[00164] The binding agents of the invention include epitope binding fragments of each of the V_HH -Fc and V_HH -IgG binding agents defined herein. Because the V_HH -Fc and V_HH -IgG binding

agents are comparable in structure to human IgG antibodies, where the variable regions are replaced by the V_HH monomers, terms for human antibody fragments are also applicable to the such binding agents. The fragments include, but are not limited to, Fab fragments, F(ab')₂ fragments, single chain Fv (scFv) antibodies, and fragments produced by an Fab expression library, as well as bi-specific antibody and triple-specific antibodies.

[00165] The V_HH-Fc and V_HH-IgG binding agents of the invention include fully human, humanized, and chimeric binding agents. The binding agents may be monoclonal or polyclonal. Further, the binding agents may be recombinant binding agents.

[00166] The binding agents may be produced in any species of animal, though preferably from a mammal such as a human, simian, mouse, rat, rabbit, guinea pig, horse, cow, sheep, goat, pig, dog or cat. For example, the binding agents can be human or humanized, or any binding agent preparation suitable for administration to a human.

Polynucleotide, Expression Vectors, Host Cells and Method of Making

[00167] The invention includes polynucleotides comprising nucleotide sequences encoding each the binding agents provided herein, as well as complementary strands thereof.

[00168] The invention also includes expression vectors comprising the polynucleotides, and host cells comprising the expression vectors. Suitable expression vectors include, e.g., pcDNA3.1 and pSec-His, as well as plasmids used to transform yeast cells into producers and secretors of the binding agents of the invention. Suitable host cells include, e.g., Chinese hamster ovary cells (CHO cells), human embryonic kidney cells 293 (HEK 293 cells), yeast cells, and insect cells.

[00169] The invention further includes methods of producing the binding agents defined herein, comprising culturing the host cells under conditions promoting expression of the binding agents encoded by the expression vectors, and recovering the binding agents from the cell cultures.

Engineered Strains of Yeast

[00170] Each of the binding agents of the invention may also be produced by engineered strains of *Saccharomyces* yeast. Accordingly, the invention is also directed to strains of *Saccharomyces* yeast, such as *S. cerevisiae* and *S. boulardii*, engineered to produce one or more

of the binding agents defined herein including, but not limited to, V_HH monomer binding agents (see Table 1), V_HH homodimer binding agents, V_HH heterodimer binding agents (see Table 3), ABAB binding agents, V_HH-Fc binding agents (see Table 5), V_HH-IgG binding agents (see Table 6), and epitope binding fragments thereof. In preferred aspects, the engineered strains of *Saccharomyces* yeast secrete the binding agents.

[00171] The identity of the *Saccharomyces* yeast strain is only limited in that it can be engineered to produce, and preferably secrete, one or more of the binding agents of the invention. In preferred aspects of the invention, the strain of *Saccharomyces* yeast engineered to produce one or more of the binding agents is *S. cerevisiae* or *S. boulardii*. The invention thus encompasses an engineered strain of *S. cerevisiae* that produces one or more of the binding agents defined herein, as well as an engineered strain of *S. cerevisiae* that secretes one or more of the binding agents defined herein. The invention also encompasses an engineered strain of *S. boulardii* that produces one or more of the binding agents defined herein, as well as an engineered strain of *S. boulardii* that secretes one or more of the binding agents defined herein. Suitable strains of yeast also include *Schizosaccharomyces pombe*, *Saccharomyces paradoxus*, and *Saccharomyces unisporus*.

[00172] *S. boulardii* is an FDA-designated Generally Regarded as Safe (GRAS) organism and it is commonly available over-the-counter for use in promoting intestinal health and amelioration of gastrointestinal illness due to diarrheal diseases. This species of yeast has been studied in multiple randomized double-blinded placebo-controlled clinical trials for both safety and efficacy against intestinal diseases including CDI [42-46]. A suitable strain of *S. boulardii* is the *S. boulardii* strain MYA796 (ATCC, Manassas, VA).

[00173] A particular example of the engineered strains of *Saccharomyces* yeast of the invention is an engineered strain of *Saccharomyces* yeast that produces a binding agent comprising a V_HH peptide monomer or linked groups of V_HH peptide monomers comprising two, three, four, or more monomers, each of which binds TcdA and/or TcdB, preferably with specificity. Thus, the invention encompasses engineered strains of *Saccharomyces* yeast that produces V_HH peptide binding agents comprising at least one V_HH peptide monomer, wherein each V_HH peptide monomer has binding specificity for an epitope of *C. difficile* toxin A (TcdA) or toxin B (TcdB). In certain aspects, these binding agents comprise two, three, four, or more linked V_HH peptide monomers. The V_HH peptide monomers include, but are not limited to, the

V_HH peptide monomers 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5), and AH3 (SEQ ID NO:7).

[00174] Another particular example of the engineered strains of *Saccharomyces* yeast of the invention is an engineered strain of *Saccharomyces* yeast that produces binding agents comprising V_HH peptide monomers joined to IgG antibodies, where the binding agents bind TcdA and/or TcdB, as defined herein. In these IgG-based binding agents, the variable regions of the light and heavy chains of IgG antibodies are replaced by one, two, three, four or more of the V_HH peptide monomers.

[00175] A further particular example of the engineered strains of *Saccharomyces* yeast of the invention is an engineered strain of *Saccharomyces* yeast that produces binding agents comprising V_HH peptide monomers joined to antibody Fc domains, where the binding agents bind TcdA and/or TcdB, as defined herein. In these Fc domain-based binding agents, one, two, three, four or more of the V_HH peptide monomers are joined to the hinge, C_H2 and C_H3 regions of each arm of Fc domain of an antibody heavy chain. Thus, the peptide monomers replace the Fab regions of an antibody.

[00176] An additional particular example of the engineered strains of *Saccharomyces* yeast of the invention is an engineered strain of *Saccharomyces* yeast that produces a tetra-specific, tetrameric binding agent, wherein the binding agent comprises linked first, second, third and fourth V_HH peptide monomers, and wherein the V_HH peptide monomers independently have binding specificity for an epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB). In certain aspects, the first, second, third and fourth V_HH peptide monomers each has binding specificity for a different epitope. In certain aspects, the two of the V_HH peptide monomers have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers have binding specificity for epitopes of TcdB. In certain aspects, the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB. Suitable V_HH peptide monomers include the AH3 monomer (SEQ ID NO:7), the AA6 monomer (SEQ ID NO:5), the 5D monomer (SEQ ID NO:1), and the E3 monomer (SEQ ID NO:3). Other monomers include, but are not limited to, those provided in Table 1.

[00177] In a preferred example, the invention is directed to an engineered strain of yeast, wherein the binding agent is ABAB, wherein the first and third monomers have binding

specificity for epitopes of TcdA and the first and third monomers are V_HH peptide monomers AH3 (SEQ ID NO:7) and AA6 (SEQ ID NO:5), respectively, and wherein the second and fourth monomers have binding specificity for epitopes of TcdB and the second and fourth monomers are V_HH peptide monomers 5D (SEQ ID NO:1) and E3 (SEQ ID NO:3), respectively.

[00178] The ABAB binding agent may comprise the amino acid sequence set forth in SEQ ID NO:19, or a sequence variant having at least 95% sequence identity thereto, wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.

[00179] The ABAB binding agent may also comprise an N-terminal secretion signal selected from the secretion signals provided in Table 4. In preferred aspects, the N-terminal secretion signal is the AT secretion signal (MRFPSIFTAVLFAASSALA (SEQ ID NO:99)) or the IVS secretion signal (MLLQAFLFLLAGFAAKISA (SEQ ID NO:103)).

[00180] The ABAB binding agent may be expressed from a plasmid within the yeast. The plasmid may be, but is not limited to, pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88). The ABAB binding agent encoded by the plasmid may comprise the amino acid sequence set forth in SEQ ID NO:107, or a sequence variant having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.

[00181] The ABAB binding agent may also be expressed from coding sequence integrated into a chromosome of yeast. The ABAB binding agent expressed from coding sequence integrated into a yeast chromosome may comprise the amino acid sequence set forth in SEQ ID NO:109, or a sequence variant having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.

[00182] The invention is also directed to engineered strains of *Saccharomyces* yeast that produce a therapeutic protein having binding specificity for a unique epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB), or both. Preferably, the engineered strain of *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*. A therapeutic protein is any protein that can bring about an improvement or cure in a medical condition in a subject, or that can inhibit or prevent a medical condition from developing in a subject. Suitable therapeutic proteins include, but are not limited to, proteins that (a) replace a protein that is deficient or abnormal; (b)

augment an existing pathway; (c) provide a novel function or activity; (d) interfere with a molecule or organism; and (e) deliver other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector proteins. Therapeutic proteins also include antibodies and antibody-based drugs, Fc fusion proteins, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics. Therapeutic proteins further include bispecific monoclonal antibodies (mAbs) and multispecific fusion proteins, mAbs conjugated with small molecule drugs, and proteins with optimized pharmacokinetics.

Methods of Making Engineered Yeast Strains

[00183] The invention is also directed to methods of engineering strains of *Saccharomyces* yeast to produce one or more of the binding agents defined herein. The means used to produce the engineered strains of yeast are not particularly limited and there are a number of well-established techniques available for engineering yeast to produce homologous and heterologous proteins that will be known to the skilled artisan. In certain aspects of these methods, *S. cerevisiae* or *S. boulardii* is engineered to produce the binding agents.

[00184] As an example, *Saccharomyces* yeast may be engineered to produce one or more of the binding agents defined herein by (a) transforming a strain of *Saccharomyces* yeast with an expression vector encoding the binding agent, and (b) screening the resulting yeast for production of the binding agent. In a certain aspect, the expression vector is plasmid pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88). While this plasmid encodes a particular ABAB binding agent, the coding region for this binding agent can be replaced by the coding region of any of the binding agents defined herein.

[00185] As a further example, *Saccharomyces* yeast may be engineered to produce one or more of the binding agents defined herein by (a) chromosomally integrating a polynucleotide sequence encoding the binding agent into the genome of the strain of *Saccharomyces* yeast, and (b) screening the yeast of (a) for production of the binding agent. In certain aspects, the chromosomal integration is performed using a CRISPR technique [85-88]. As an example, such a method may include the steps of: (a) amplifying a polynucleotide sequence encoding the ABAB binding agent from plasmid pCEV-G4-Km-TEF-AT-yABAB hAA6T83N-tagless (SEQ ID NO:90) using primers containing (i) nucleic acid sequence homologous to a selected yeast

chromosomal integration site and (ii) nucleic acid sequence homologous to regions 5' and 3' of ABAB binding agent coding sequence of the plasmid, to produce an integration cassette, (b) transforming yeast with the integration cassette produced in (a) with pCRI-Sb- δ 1 (SEQ ID NO:91) or pCRI-Sb- δ 2 (SEQ ID NO:92) to induce a double stranded break within the corresponding yeast chromosomal delta sites under conditions promoting spontaneous integration of the integration cassette into the site of the double stranded break, (c) screening the transformed yeast of (b) for production of the ABAB binding agent.

[00186] While the plasmid pCEV-G4-Km-TEF-AT-yABAB hAA6T83N-tagless encodes a particular ABAB binding agent, the coding region for this binding agent can be replaced by the coding region of any of the binding agents defined herein.

[00187] Suitable means used to screen the yeast for production of the binding agents will be readily apparent to the skilled artisan and include, but are not limited to immunoassays, such as an ELISA or a western blot.

Methods of Treatment and Prevention

[00188] The binding agents and engineered strains of *Saccharomyces* yeast of the invention can be used in methods of treating or preventing a disease symptom induced by *C. difficile* in a subject. These methods generally comprise administering a therapeutically-effective amount of one or more binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection. In certain aspects of this embodiment, the disease symptom induced by *C. difficile* is diarrhea

[00189] The binding agents and engineered strains of *Saccharomyces* yeast of the invention can also be used in of neutralizing *C. difficile* toxin TcdA and/or TcdB in a subject infected by *C. difficile*. These methods generally comprise administering a therapeutically-effective amount of one or more binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject having *C. difficile* infection.

[00190] The binding agents and engineered strains of *Saccharomyces* yeast of the invention can further be used in methods of treating *C. difficile* infection in a subject. These methods generally comprise administering a therapeutically-effective amount of one or more of the binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein

to a subject having *C. difficile* infection. These same methods can be used to treat CDI, as defined herein.

[00191] The binding agents and engineered strains of *Saccharomyces* yeast of the invention can also be used in methods of maintaining normal bowel function in a subject having a *C. difficile* infection. These methods generally comprise administering a therapeutically-effective amount of one or more of the binding agents and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

[00192] The binding agents and engineered strains of *Saccharomyces* yeast can also be used in immunoprophylaxis in order to prevent immediate CDI threats. In addition, passive immunoprophylaxis can be used to prevent both immediate and longer-term CDI threats. Each approach has its own particular advantages and is suitable to target a particular high-risk population. These methods generally comprises administering a therapeutically-effective amount of one or more of the binding agent and/or one or more engineered strains of *Saccharomyces* yeast as defined herein to a subject a risk of developing *C. difficile* infection.

[00193] In preferred aspects of the methods of the invention, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[00194] Each of the methods of the invention may include administration of the one or more binding agents and/or the one or more engineered strains of *Saccharomyces* yeast in one or more pharmaceutical formulations comprising the binding agents and/or the engineered strains of *Saccharomyces* yeast and a pharmaceutically acceptable carrier or diluent. In preferred aspects, the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

[00195] As used herein, the terms “treat”, “treating”, and “treatment” have their ordinary and customary meanings, and include one or more of: blocking, ameliorating, or decreasing in severity and/or frequency a symptom of a *C. difficile* infection or a *C. difficile*-related disease (CDI) in a subject; and/or partly or fully inhibiting the biological activity and/or promoting the immunologic clearance of *C. difficile* TcdA and/or TcdB in a subject infected with *C. difficile*; and/or growth, division, spread, or proliferation of *C. difficile* cells or a *C. difficile* infection in a subject. Treatment means blocking, ameliorating, decreasing, or inhibiting by about 1% to about 100% versus a subject in which the methods of the present invention have not been practiced. Preferably, the blocking, ameliorating, decreasing, or inhibiting is about 100%, 99%, 98%, 97%,

96%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or 1% versus a subject in which the methods of the present invention have not been practiced.

[00196] As used herein, the terms “prevent”, “preventing” and “prevention” have their ordinary and customary meanings, and include one or more of, stopping, averting, avoiding, alleviating or blocking *C. difficile* from colonizing, developing or progressing in a subject; and/or partly or fully inhibiting the biological activity and/or toxic effects of TcdA and/or TcdB in a subject infected with *C. difficile*; and/or stopping, averting, avoiding, alleviating or blocking the growth, division, spread, or proliferation of bacterial cells or bacterial infection in a subject. Prevention means stopping by at least about 95% versus a subject to which the prevention has not been administered. Preferably, the stopping is about 100%, about 99%, about 98%, about 97%, about 96% or about 95%. The results of the prevention may continue for a period of days (such as 1, 2, 3, 4, 5, 6 or 7 days), weeks (such as 1, 2, 3 or 4 weeks) or months (such as 1, 2, 3, 4, 5, 6 or more months).

[00197] The method of treating and preventing provided herein can be supplemented by also administering a therapeutically-effective amount of an antibiotic to the subject. Preferably, the antibiotic will have antibacterial activity against *C. difficile*.

Pharmaceutical Formulations

[00198] While the binding agents and engineered strains of *Saccharomyces* yeast may be administered directly to a subject, the methods of the present invention are preferably based on the administration of a pharmaceutical formulation comprising one or more binding agents and/or one or more engineered strains of *Saccharomyces* yeast, and a pharmaceutically acceptable carrier or diluent. Thus, the invention includes pharmaceutical formulations comprising one or more of the binding agents and/or one or more engineered strains of *Saccharomyces* yeast defined herein and a pharmaceutically acceptable carrier or diluent.

[00199] Pharmaceutically acceptable carriers and diluents are commonly known and will vary depending on the particular binding agent or engineered strains of *Saccharomyces* yeast being administered and the mode of administration. Examples of generally used carriers and diluents include, without limitation: saline, buffered saline, dextrose, water-for-injection, glycerol, ethanol, and combinations thereof, stabilizing agents, solubilizing agents and surfactants, buffers and preservatives, tonicity agents, bulking agents, and lubricating agents. The formulations

comprising binding agents and/or engineered strains of *Saccharomyces* yeast will typically have been prepared and cultured in the absence of any non-human components, such as animal serum (e.g., bovine serum albumin).

[00200] Pharmaceutical formulations comprising one or more binding agents and/or one or more engineered strains of *Saccharomyces* yeast may be administered to a subject using modes and techniques known to the skilled artisan. Characteristic of CDI disease may make it more amenable to treatment and prevention using colonic delivery of therapeutic agents, i.e., targeted delivery of binding agents to the lower GI tract, e.g., the large intestine or colon. Other modes of delivery include, but are not limited to, oral, nasal, anal, and via intravenous injection or aerosol administration. Other modes include, without limitation, intradermal, subcutaneous (s.c., s.q., sub-Q, Hypo), intramuscular (i.m.), intraperitoneal (i.p.), intra-arterial, intramedullary, intracardiac, intra-articular (joint), intrasynovial (joint fluid area), intracranial, intraspinal, and intrathecal (spinal fluids).

[00201] Depending on the means of administration, the dosage may be administered all at once, such as with an oral formulation in a capsule or liquid, or slowly over a period of time, such as with an intramuscular or intravenous administration.

[00202] The amount of binding agents, alone or in a pharmaceutical formulation, administered to a subject is an amount effective for the treatment or prevention of infection. Thus, therapeutically effective amounts are administered to subjects when the methods of the present invention are practiced. In general, between about 1 ug/kg and about 1000 mg/kg of the binding agent per body weight of the subject is administered. Suitable ranges also include between about 50 ug/kg and about 500 mg/kg, and between about 10 ug/kg and about 100 mg/kg. However, the amount of binding agent administered to a subject will vary between wide limits, depending upon the location, source, extent and severity of the infection, the age and condition of the subject to be treated, the means of administration, etc. A physician will ultimately determine appropriate dosages to be used.

[00203] The amount of the engineered strains of *Saccharomyces* yeast, alone or in a pharmaceutical formulation, administered to a subject is an amount effective for the treatment or prevention of infection. Thus, therapeutically effective amounts are administered to subjects when the methods of the present invention are practiced. In general, between about 1 ug/kg and about 1000 mg/kg of the engineered strains of *Saccharomyces* yeast per body weight of the

subject is administered. Suitable ranges also include between about 50 ug/kg and about 500 mg/kg, and between about 10 ug/kg and about 100 mg/kg. However, the amount of the engineered strains of *Saccharomyces* yeast administered to a subject will vary between wide limits, depending upon the location, source, extent and severity of the infection, the age and condition of the subject to be treated, the means of administration, etc. A physician will ultimately determine appropriate dosages to be used.

[00204] Administration frequencies of the binding agents, the engineered strains of *Saccharomyces* yeast, and pharmaceutical formulations comprising the binding agents and/or engineered strains of *Saccharomyces* yeast will vary depending on factors that include the location of the bacterial infection, the particulars of the infection to be treated or prevented, and the mode of administration. Each formulation may be independently administered 4, 3, 2 or once daily, every other day, every third day, every fourth day, every fifth day, every sixth day, once weekly, every eight days, every nine days, every ten days, bi-weekly, monthly and bi-monthly.

[00205] The duration of treatment or prevention will be based on location and severity of the infection being treated or the relative risk of contracting the infection, and will be best determined by the attending physician. However, continuation of treatment is contemplated to last for a number of days, weeks, or months.

[00206] In each embodiment and aspect of the invention, the subject is a human, a non-human primate, bird, horse, cow, goat, sheep, a companion animal, such as a dog, cat or rodent, or other mammal. The subjects to which the methods of the present invention can be applied include subjects having an underlying disease or condition that makes them more susceptible to *C. difficile* infections.

[00207] The invention also provides a kit comprising one or more containers filled with one or more of the binding agents, one or more of the engineered strains of *Saccharomyces* yeast, or one or more pharmaceutical formulations comprising binding agents and/or the engineered strains of *Saccharomyces* yeast. The kit may also include instructions for use. Associated with the kit may further be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

III. Examples

V_HH Monomer and Heterodimer binding agents

[00208] An efficient platform to screen single domain (monomeric), mono-specific V_HH peptide monomers against specific domains of toxins TcdA and TcdB was established. Using highly immunogenic atoxic holotoxins for immunization, and bioactive chimeric toxins (with normal domain functions) for screening, panels of V_HH monomers binding to different domains of TcdA or TcdB were prepared. A majority of these V_HH monomers possessed potent neutralizing activity and their binding to specific domains was determined (Fig. 2). The atoxic holotoxins have point mutations at their enzymatic glucosyltransferase domains as described previously [33]. The bioactive chimeric toxins were created by switching the functional domains between TcdA and TcdB, which was also described previously [33].

[00209] Several of the V_HH monomers bind to highly conserved TcdA/TcdB epitopes. For example, V_HH E3 binds to the Rho GTPase binding site and blocks glucosylation; V_HH AH3 binds to the GT domain of the toxin; V_HH 7F binds to cysteine protease cleavage sites and blocks GT domain cleavage and release. Some V_HH monomers have potent neutralizing activity capable of blocking toxin cytotoxic activity at nM concentrations (See Table 1; Figs. 3A and 3B).

[00210] To enhance the binding activity, two domain (dimeric), bi-specific V_HH heterodimers were created (Table 3; Fig. 3C), allowing a single protein to target two distinctive epitopes of the toxins. These bi-specific V_HH heterodimers possessed substantially enhanced neutralizing activities compared with equimolar mixtures of the same two V_HH monomers (Fig. 3D). Heterodimers 5D/E3 and AH3/AA6 were found to fully protect mice from lethal systemic TcdB or TcdA challenge respectively, whereas mixed 5D and E3, or AA6 alone were only partially protective (Figs. 3E and 3F).

[00211] A tetra-valent, tri-specific V_HH binding agent (ABA) was generated by genetically fusing V_HHs with the highest neutralizing activities targeting conserved, non-overlapping epitopes (AH3/E3/E3/AA6) [41]. This rationally designed toxin binder achieved a substantially enhancing binding affinity and neutralizing activity over the individual monomers and potent therapeutic efficacy against fulminant CDI. ABA was able to broadly neutralize toxins from 11

different TcdA⁺TcdB⁺ *C. difficile* clinical isolates but failed to neutralize TcdB derived from two TcdA⁻TcdB⁺ strains. The amino acid sequence of ABA is set forth in SEQ ID NO:111.

[00212] The V_HH monomers comprising the heterodimers were linked using a flexible linker selected from SEQ ID NOs:9-13 (Table 2).

ABAB Binding Agent

[00213] Four domain (tetrameric), tetra-specific V_HH binding agents were generated by linking V_HH monomers AH3, 5D, E3, and AA6, namely ABBA (AH3/5D/E3/AA6) and ABAB (AH3/5D/AA6/E3). These tetra-specific, tetrameric binding agent targets conserved, non-overlapping epitopes and had excellent toxin neutralizing activity. In the design of ABAB (Fig. 4), V_HH peptide monomers AH3 and AA6 were separated by placing the 5D monomers between them because AH3 and AA6 bind to GT and TD respectively (Fig. 2), which are spatially distant to each other. This design allowed AH3 and AA6 to bind to TcdA simultaneously.

[00214] In the construction of the ABAB binding agent, flexible linkers were placed between the V_HH monomers (see Fig. 4). The complete nucleic acid sequence encoding ABAB is provided in SEQ ID NO:20; the amino acid sequence of the protein is provided in SEQ ID NO:19.

[00215] In certain variants, a His₍₆₎-tag was provided at the amino terminus of the protein to aid in purification, an E-tag was provided at the carboxy terminus of the protein to aid in detection, and/or an albumin-binding peptide (ABP, DICLPRWGCLWD; SEQ ID NO:21) was placed at the carboxyl end of the construct to increase serum half-life of the protein (See Fig. 4).

[00216] ABAB was found to exhibit substantial enhanced binding affinity (Table 7) and neutralizing activity (Table 8) over the individual monomers and ABA. In Table 8, Vero cells were exposed to 5 ng/ml of TcdA in the presence of serially diluted AA6, AH3, ABAB or Merck anti-TcdA HuMab [9]. The minimal doses of antibodies protecting cells from TcdA-induced cell rounding are shown.

Table 7

	V_HHs	K_{on} (M⁻¹s⁻¹)	K_{off} (s⁻¹)	K_D (nM)
TcdA	AH3	2.20 x 10 ⁴	7.10 x 10 ⁻⁴	32.0
	AA6	3.52 x 10 ⁴	6.92 x 10 ⁻⁴	19.7
	ABAB	6.96 x 10⁵	1.21 x 10⁻⁶	0.002
TcdB	5D	1.52 x 10 ⁶	9.94 x 10 ⁻⁴	0.65
	E3	2.95 x 10 ⁶	9.4 x 10 ⁻⁵	0.03
	ABAB	1.79 x 10⁶	3.57 x 10⁻⁶	0.002

Table 8

AA6	AH3	ABAB	Merck Anti-TcdA HuMab
8 nM	8 nM	0.25 nM	> 10 nM

[00217] ABAB was also found to compete with all four individual V_HH peptide monomers in a competition ELISA and can simultaneously bind to both TcdA and TcdB as determined by sandwich ELISA. Furthermore, ABAB is broadly reactive, capable of neutralizing toxins from the 13 different *C. difficile* strains that represent most of the current epidemic strains (Table 9).

Table 9

Strains	Ribotype	REA type	PFGE type	Toxins	Place/date of isolation	ABAB neutralization
R20291	27	BI	NAP1	TcdA/TcdB	London/2006	Yes
CD196	27	BI	NAP1	TcdA/TcdB	France/1985	Yes
630	12	R		TcdA/TcdB	Zurich/1982	Yes
M120	78	BK	NAP7,8,9	TcdA/TcdB	UK/2007	Yes
BI-9	1	J	NAP2	TcdA/TcdB	Gerding Collection	Yes
Liv024	1	J	NAP2	TcdA/TcdB	Liverpool/2009	Yes
Liv022	106	DH	NAP11	TcdA/TcdB	Liverpool/2009	Yes
TL178	2	G	NAP6	TcdA/TcdB	Belfast/2009	Yes
TL176	14	Y	NAP4	TcdA/TcdB	Cambridge, UK/2009	Yes
TL174	15			TcdA/TcdB	Cambridge, UK/2009	Yes
CD305	23			TcdA/TcdB	London/2008	Yes
CFS	17			TcdB	Belgium/1995/human	Yes
M68	17			TcdB	Dublin/2006/human	Yes

[00218] Since ABAB shows high potency in binding to and neutralizing both toxins, its efficacy in treating fulminant CDI was evaluated. A single injection with as low as 40 µg/kg of ABAB one-day post *C. difficile* spore challenge reversed fulminant CDI in mice. None of the ABAB-treated mice died whereas 50% of control mice became moribund by 3 days post-infection (Fig. 5A). ABAB is 4-log more potent in preventing mortality after systemic challenge with TcdA and TcdB than the Merck HuMabs (Fig. 5B) [9]. Thus, ABAB possesses extraordinary *in vivo* efficacy against *C. difficile* toxins and spore challenge.

[00219] Animal and human studies demonstrated that passively administered antitoxin antibodies provide protection against CDI. The initial studies here also showed that antitoxin polysera protected mice from primary CDI (Figs. 6A and 6B) and recurrent/relapse CDI. These findings and results from Figs. 5A and 5B supported the hypothesis and provided the rationale for development of a parenteral ABAB immunization strategy for preventing CDI. To achieve the goal of optimizing ABAB for systemic delivery, chimeric and humanized ABAB were generated as illustrated in Figure 1, i.e., V_HH-Fc and V_HH-IgG binding agents as well as the humanized proteins *h*V_HH-Fc and *h*V_HH-IgG, after which leading proteins were evaluated for *in vivo* neutralizing activity and protection in animal models. Details regarding the preparation and testing of the additional binding agents are provided in the following paragraphs.

ABAB-Fc

[00220] ABAB-Fc binding agent was prepared by generating an expression vector encoding the V_HH peptide monomers AH3/5D/AA6/E3 (linked in the noted order) joined to a human IgG1 Fc domain. The V_HH peptide monomers were separated by flexible linkers of Table 2. The nucleic acid sequence encoding the protein is provided in SEQ ID NO:23. ABAB-Fc was expressed and purified from stable transfected HEK293 cell line culture supernatant using protein A beads under conditions permitting disulfide bond formation and bi-valent molecule production. The expression levels were about 20 mg/L of culture supernatant. ABAB-Fc is fully functional in binding and neutralizing both TcdA and TcdB (data not shown). The amino acid sequence of ABAB-Fc is provided in SEQ ID NO:22.

[00221] Mono-specific V_HH-Fc binding agents (AH3-Fc, 5D-Fc, E3-Fc, AA6-Fc) and bi-specific V_HH-Fc binding agents (AH3/5D-Fc) and AA6/E3-Fc) were also made using this Fc-fusion system. Table 5 above provides the sequences for these additional binding agents.

ABAB-IgG

[00222] As illustrated in Figure 1, bi-specific $V_{\text{H}}\text{H-IgG}$ (AH3/5D-IgG and E3/AA6-IgG) can be generated by fusing monomers with human IgG heavy and light (kappa or lambda) chains separately. Tetra-specific $V_{\text{H}}\text{H-IgG}$ (ABAB-IgG) binding agents can be generated by fusing dimers with human IgG heavy and light chains separately. Co-transfecting the heavy and light chain constructs generates the AH3/5D-IgG, E3/AA6-IgG and ABAB-IgG chimeric proteins. The separation of two $V_{\text{H}}\text{H}$ s into heavy and light chains likely improves the yield and stability of bi-specific and tetra-specific $V_{\text{H}}\text{H}$ chimeric proteins. This allows determination of whether $V_{\text{H}}\text{H}$ -human IgG chimeric antibody helps the stability and efficacy of ABAB *in vivo*. Similarly, further improvement of *in vivo* half-life of ABAB-IgG can also be tested in ABAB-IgG variants with enhanced binding affinity to FcRn receptor.

[00223] Bi-specific (AH3/5D-IgG1 and E3/AA6-IgG1) and tetra-specific (ABAB-IgG1) IgG1 binding agents were prepared by co-transfecting expression vectors encoding the heavy and light (kappa) chain of each binding agent. The $V_{\text{H}}\text{H}$ peptide monomers were separated by flexible linkers of Table 2.

[00224] Bi-specific, tetrameric $V_{\text{H}}\text{H-IgG1}$ binding agents were produced by preparing two separate expression vectors, the first encoding a $V_{\text{H}}\text{H}$ peptide monomer joined to the human IgG1 antibody heavy chain (CH1-Hinge-CH2-CH3) lacking the heavy chain variable region and the second encoding a $V_{\text{H}}\text{H}$ peptide monomer joined to the human IgG1 antibody light (kappa) chain (CK) lacking the light chain variable region. These binding agents are bi-specific and tetrameric in that each light chain of the resulting binding agent is linked to a first $V_{\text{H}}\text{H}$ monomer and each heavy chain of the resulting binding agent is linked to a second $V_{\text{H}}\text{H}$ monomer. Table 6 above provides the sequences for these additional binding agents. Suitable pairings include (i) AH3-IgG1-heavy chain + AA6-light (kappa or lambda) chain, (ii) 5D-IgG1-heavy chain + E3-light (kappa or lambda) chain, (iii) 5D-IgG1-heavy chain + AA6-light (kappa or lambda) chain, and (iv) AH3-IgG1-heavy chain + E3-light (kappa or lambda) chain.

[00225] Tetra-specific, octameric ABAB-IgG binding agents were prepared. These binding agents are tetra-specific and octameric in that each light (kappa or lambda) chain of the resulting binding agent is joined to two (a first and second) linked $V_{\text{H}}\text{H}$ monomers and each heavy chain

of the resulting binding agent is joined to a two (a third and fourth) linked V_HH monomer, where the first, second, third and fourth monomers binds to a different epitope.

[00226] A particular tetra-specific, octameric ABAB-IgG (Figure 7) binding agent was produced by preparing two separate expression vectors, the first encoding the V_HH peptide monomers AH3/5D (linked in the noted order) joined to the human IgG1 antibody heavy chain (CH1-Hinge-CH2-CH3) lacking the heavy chain variable region and the second encoding the V_HH peptide monomers AA6/E3 (linked in the noted order) joined to the human IgG1 antibody light (kappa) chain (CK) lacking the light chain variable region. The nucleotide sequence encoding the AH3/5D-IgG1 heavy chain is provided in SEQ ID NO:45; the amino acid sequence is provided in SEQ ID NO:44. The nucleotide sequence encoding the AA6/E3-IgG1 kappa chain is provided in SEQ ID NO:47; the amino acid sequence is provided in SEQ ID NO:46.

[00227] The bi-specific (AH3/5D-IgG1 and E3/AA6-IgG1) and tetra-specific (ABAB-IgG1) IgG1 binding agents were expressed and purified from stable transfected HEK293 cell line culture supernatant using protein A beads under conditions permitting disulfide bond formation and bi-valent molecule production. SDS-PAGE shows more than 90% purity of the purified ABAB-IgG1 with total molecular weight (light and heavy chains together) around 218 KDa on non-reduced gel (data not shown). The molecular weight of heavy chain is 68 KDa and light chain is 41 KDa showed on reduced gel.

[00228] The binding of ABAB-IgG1 to TcdA and TcdB was determined. Figures 8A-8B illustrate the comparison of binding ABAB-IgG1 to both toxins with the individual components (AH3, AA6, E3, and 5D). Fig. 8A shows the results of experiments where plates were coated with 1 ug/ml TcdA (TxA). Serially diluted ABAB-IgG was added in concentrations of 0, 0.64, 3.2, 16, 80, 400 and 2,000 ng/ml. The plates were washed and Merck Ab (anti-TcdA), Fc-ABBA (ABAB-Fc), Habab (ABAB-IgG), and V_HH anti-TcdB monomers AA6 and AH3 were added in the indicated amounts (ng/ml). Appropriate labeled antibodies were used for detection. Fig. 8B shows the results of experiments where plates were coated with 1 ug/ml TcdB (TxB). Serially diluted ABAB-IgG was added in concentrations of 0, 0.64, 3.2, 16, 80 and 400 ng/ml. The plates were washed and Merck Ab (Anti-TcdB), Fc-abba (ABAB-Fc), Habab (ABAB-IgG), and V_HH anti-TcdB monomers E3 and 5D were added in the indicated amounts (ng/ml). Appropriate labeled antibodies were used for detection.

[00229] As expected, the tetra-specific antibody can bind to TcdA and TcdB simultaneously as determined by sandwich ELISA (Figures 9A-9B). In a first set of experiments, plates were coated with 1 ug/ml TcdA (TxA). Serially diluted ABAB-IgG (Habab) was added in concentrations of 0, 1.6, 8, 40, 200 and 1000 ng/ml. The plates were washed and the following amounts of TcdB were added: 1.6, 8, 40, 200, and 1000 ng/ml. Mouse anti-TxB antibodies (500x) and goat anti-mouse-IgG-HRP (3000x) antibodies were used for detection. The results provided in Fig. 9A show that TxB is detected by coating TxA, suggesting IgG-ABAB binds to TxA/B simultaneously. In a second set of experiments, plates were coated with 1 ug/ml TcdB (TxB). Serially diluted ABAB-IgG (Habab) was added in concentrations of 0, 1.6, 8, 40, 200 and 1000 ng/ml. The plates were washed and the following amounts of TcdA were added: 1.6, 8, 40, 200, and 1000 ng/ml. Mouse anti-TxA antibodies (500x) and goat anti-mouse-IgG-HRP (3000x) antibodies were used for detection. The results provided in Fig. 9B show that TxA is detected by coating TxB, again suggesting IgG-ABAB binds to TxA/B simultaneously.

[00230] The neutralizing activities of ABAB-IgG1 against cytopathic effects of the toxins on cultured cells were also examined. TcdA (100 ng/ml, Fig. 10A) was mixed with serially diluted Merck anti-TcdA human monoclonal antibody, ABAB-IgG1 (Hababa), and V_HH anti-TcdA monomers AA6 and AH3 before adding to Vero cell monolayers in 100 ul culture medium and incubated at 37 °C for 24 hours. The results provided in Fig. 10A show that ABAB-IgG1 is at least 1000-fold more potent than Merck antibodies in neutralizing TcdA. In similar experiments, TcdB (10 pg/ml, Fig. 10B) was mixed with serially diluted Merck anti-TcdB human monoclonal antibody, ABAB-IgG1 (Hababa), and V_HH anti-TcdB monomers E3 and 5D before adding to Vero cell monolayers in 100 ul culture medium and incubated at 37 °C for 24 hours. The results provided in Fig. 10B show that ABAB-IgG1 is at least 1000-fold more potent than Merck antibodies in neutralizing TcdB.

[00231] The *in vivo* neutralizing activities of ABAB-IgG1 were studied in a mouse model of CDI, the results of which are shown in Figure 11. Mice were challenged with lethal dose of a mixed TcdA and TcdB (25 ng each toxin per mouse) and 4 hour later, ABAB-IgG (10, 30 or 100 ug/kg), a mixture of Merck anti-toxin A and anti-toxin B antibodies (10 mg/kg) or PBS was administered to the mice. The results demonstrate that the neutralizing activity of ABAB-IgG was much greater than the Merck antibody, and at lower concentrations.

Animal Testing of ABAB-IgG

[00232] The ABAB-IgG binding agent was tested in both prophylactic treatment and re-challenge survival assays. Figure 12 provides the experimental design of both studies. 6 - 8 week old female C57 mice were used, and the conditions included PBS: 10ml/kg, i.p., n = 14; ABAB-IgG: 200ug/kg, i.p., n = 10; ABAB-IgG: 1mg/kg, i.p., n = 10; ABAB-IgG: 5mg/kg, i.p., n = 10.

[00233] Table 10 provides a summary of the results seen with prophylactic treatment of mice against *C. difficile* spores (UK1, a 027/BI/NAP1 epidemic strain). ABAB-IgG or PBS was administered one day prior to administrating of *C. difficile* spores. As can be seen, ABAB-IgG showed dose-related prophylactic protection against CDI, where 5mg/kg showed complete protection on all the parameters examined and 200ug/kg was found to be more potent than 200ug/kg of bi-specific V_HH fusion antibody ABA [41].

Table 10

	Diarrhea			Weight Change				Survival
	Occurrence	Day 1 score	Day 2 score	Overall	Day 2	Day 3	Day 4	
200 ug/kg		–	–	–	√	–	√	√
1 mg/kg	√	–	√	–	√	√	–	√
5 mg/kg	√	√	√	√	√	√	√	√

[00234] Table 11 provides a summary of the results seen with re-challenge of mice against *C. difficile* spores. ABAB-IgG or PBS was administered 15 days prior to administrating of *C. difficile* spores. As can be seen, one dose of ABAB-IgG showed some protection against the CDI caused by re-challenge of spores, but the protection was much less efficient compared to that during the primary challenge. This may be due to the drop of the antibody level with time and the generation of antibody in the PBS group following primary challenge.

Table 11

	Diarrhea			Weight Change				Survival
	Occurrence	Day 1 score	Day 2 score	Overall	Day 2	Day 3	Day 4	
200 ug/kg	√	√	–	–	–	–	–	–
1 mg/kg	√	–	–	–	–	–	√	–
5 mg/kg	–	–	–	√	–	–	–	–

[00235] Intestinal delivery of IgG-ABAB was also tested for protection of mice from fulminant CDI. After a single IgG-ABAB injection into mouse ceca after a laparotomy, mice were completely protected against fulminant CDI of death outcomes whereas 50% of control mice succumbed (data not shown). Disease progress and severity were assessed daily using a clinical scoring system modified from a previous publication [62], which included four criteria (activity level, posture, coat, and diarrhea) each graded on a scale from 0 to 4 and added together to generate a score with a maximum value of 16. A normal mouse would score 0 and a mouse found dead was scored as 16. Mice with scores equal to or higher than 11 should be euthanized. Only one mouse in the IgG-ABAB treatment group developed transient diarrhea whereas mice injected with PBS developed severe CDI disease symptoms (data not shown). Thus, Ig-ABAB manually delivered by injection into mouse intestines showed potent therapeutic efficacy.

Expression, purification and evaluation of binding agents

[00236] A variety of selection criteria is used to select the binding agents generated in the experiments described in the approaches herein. First, each of the constructs defined herein can be used in transient transfections of 293T cells for making small-scale recombinant proteins by Protein A affinity chromatography. The production yield of each construct can be determined by quantitative ELISA. Second, binding activity of recombinant proteins can be screened using ELISA and surface plasmon resonance (SPR) to select constructs that preserve their original binding activities against the toxins. Third, the proteins are evaluated for neutralizing activity in *in vitro* assays (Fig. 3).

[00237] Accumulating observations indicate that polyreactivity and/or autoreactivity of *in vivo* recombinant binding agents are potential issues related to their *in vivo* safety and half-life. The application of the selected ABAB binding agents as a systemic binding agent for preventing primary acute CDI likely requires that the chimeric and humanized ABAB proteins are limited in polyreactivity and/or autoreactivity. Progress in protein proteomics has made it possible to screen for polyreactivity and autoreactivity of recombinant antibodies *in vitro*, which is a great tool for surrogate therapeutic antibodies. Therefore, selected humanized binding agents with good yield, high binding affinity, and potent neutralizing activity can be further tested for

potential polyreactivity and autoreactivity using the auto-antigen microarray test and ProtoArray protein microarrays (Invitrogen).

[00238] From the above *in vitro* assays, candidate ABAB-Fc and ABAB-IgG binding agents can be evaluated for their *in vivo* toxicity, serum half-life, and immunogenicity.

Generation of *S. cerevisiae* secreting ABAB (Sc-ABAB)

[00239] Means for *in vivo* production and delivery of the binding agents to the gut of subjects having CDI or at risk of developing CDI were developed. Because *S. cerevisiae* is genetically similar to *S. boulardii* [52,53] and genetic tools are readily available for *S. cerevisiae*, *S. cerevisiae* was first used for ABAB secretion validation.

[00240] A novel bi-specific sandwich ELISA method was first developed to evaluate ABAB secretion. The setting utilizes purified TcdA and TcdB as binding antigens for ABAB bispecificity and α -TcdA antibodies for detection (Fig. 13A). For standardization, plates were coated with TcdB (1 ug/ml) into which was added serially diluted ABBA ((AH3-E3-E3-AA6)) standard. Serially diluted rTcdA (1ug/ml to 7.8 ng/ml) was then added. The capture of TcdA was then measured by adding monoclonal antibody against TcdA followed by HRP conjugated secondary antibody. The results for the standard curves are shown in Fig. 13B. Based on these results, a standard curve derived using 125ng/ml of rTcdA was chosen for determining secretion levels of ABAB in yeast culture supernatants and used for all subsequent ELISA.

[00241] A shuttle plasmid (pD1214-FAKS) containing origins of replication from both *E. coli* (pUC) and yeast (2 micron circle), as well as a yeast auxotrophic selection marker URA3 (conferring the ability to synthesize uracil), was obtained from DNA 2.0 (Newark, CA). The sequence encoding ABAB (SEQ ID NO:20), and His tag (SEQ ID NO:66) and D7 tag (SEQ ID NO:112) at the N-terminus and C-terminus of ABAB respectively, was inserted into this plasmid backbone in which transcription was controlled by the strong constitutive yeast translational elongation factor promoter (P_{TEF}) and extracellular secretion provided by fusion to the alpha mating factor secretion signal leader sequence (FAKS). The sequence of the resulting plasmid (pD1214-FAKS-His-hABAB-D7) is provided in SEQ ID NO:68.

[00242] Plasmid pD1214-FAKS-His-hABAB-D7 was transformed into the *S. cerevisiae* strain BY4741 (MATa his3 Δ 1 leu2 Δ 0 Met15 Δ 0 ura3 Δ 0), an URA3 knockout S288C-derivative laboratory strain. Yeast transformants were then cultured in YNB medium containing dropout

mix without uracil (6.8g YNB, 20g glucose, 2g dropout mix in 1L of sterile ddH₂O) at 250 rpm at 30 °C overnight to reach O.D. 1 in a shaker. The cells were then centrifuged down and lysed by sonication in 1X SDS loading buffer. After sonication, total cell lysates were treated at 98°C for 5 minutes before loading on a SDS gel. Same amount of yeast control cell lysates were loaded in each well except the control cells were not viable in YNB medium without uracil and therefore were cultured in YNB complimented with uracil.

[00243] Culture supernatants from 25 yeast transformants as well as 3 yeast control colonies were centrifuged to spin down cells, and the cell-free supernatants were then diluted with 2.5% milk in PBS containing 0.05% of tween 20 at 1:3 ratio and screened by the ELISA as described above after 24 hrs of incubation in a shaker at 250 rpm and 30 °C. Fig. 14B shows that all the yeast transformants secreted ABAB in culture supernatant compared to the culture supernatant from the yeast control colonies.

[00244] A cell-based neutralizing assay was used to assess the biological activity of secreted ABAB in culture supernatant. In this assay, sufficient amount of toxin A or toxin B to cause 100% cell rounding in 4 hours were added with PBS, cell-free culture supernatant from BY4741 control colony or BY4741-ABAB colony. Recombinant ABAB was used a positive control. The biological activity of secreted ABAB in culture supernatant was determined by the level of neutralizing activity to prevent cell rounding. Full length ABAB secreted from *S. cerevisiae* indeed retains its neutralizing activity when compared with purified recombinant ABAB (Fig. 14A). These combined results imply the plausibility of ABAB secretion by *S. boulardii*.

[00245] In further experiments, it was demonstrated that oral gavage of mice with Sc-ABAB at doses of 10¹⁰ CFU had no adverse effects on mice, and mice shed live Sc-ABAB as determined by plating feces on Sabouraud CAF-Agar (data not shown). Isolates recovered from mice retained their ability to produce functional ABAB using the assay described above.

ABAB Secretion Optimization

[00246] ABAB secretion level is imperatively linked to *in vivo* therapeutic efficacy. Therefore, the possibility of further optimizing ABAB secretion by replacing the existing FAKS secretion signal with a number of commercially available secretion signals was explored. Secretion sequences facilitate co-translational or post-translational translocation of heterogeneous proteins into the endoplasmic reticulum and Golgi compartments prior to

extracellular export. Although α -mating factor is a commonly used signal sequence for heterologous protein secretion that typically generates good yields of the secreted proteins in *S. cerevisiae* [69,70], studies have shown that other secretion sequences from other proteins such as inulinase or invertase could be more suitable for secreting certain heterologous proteins [71,72].

[00247] 11 different commercially available secretion signals (Table 4; DNA 2.0, Newark, CA) were genetically fused with ABAB individually under the control of TEF promoter in the same pD1214 plasmid backbone. Plasmids encoding ABAB with alternative secretion signals include the following plasmids where the FAKS secretion signal is replaced by the noted new secretion signals from Table 4 and where both the his-tag and D7-tag are removed:

Plasmid pD1214-AKS-hABAB (SEQ ID NO:70)

Plasmid pD1214-AK-hABAB (SEQ ID NO:71)

Plasmid pD1214-AT-hABAB (SEQ ID NO:72)

Plasmid pD1214-AA-hABAB (SEQ ID NO:73)

Plasmid pD1214-GA-hABAB (SEQ ID NO:74)

Plasmid pD1214-IN-hABAB (SEQ ID NO:75)

Plasmid pD1214-IVS-hABAB (SEQ ID NO:76)

Plasmid pD1214-KP-hABAB (SEQ ID NO:77)

Plasmid pD1214-LZ-hABAB (SEQ ID NO:78)

Plasmid pD1214-SA-hABAB (SEQ ID NO:79)

In addition, both the his-tag and D7-tag in the original ABAB construct (pD1214-FAKS-His-hABAB-D7) were removed to produce plasmid pD1214-FAKS-hABAB (SEQ ID NO:69) and culture incubation temperature was raised to 37°C to better accommodate *in vivo* and clinical testing relevant scenarios. All 11 plasmids were then transformed in BY4741 and 5 independent colonies from each selective plate were selected to generate culture supernatants. The amount of secreted ABAB was determined by the same ELISA as described above. In addition, E/O value was used to provide a fair comparison across all groups. E/O value is defined by ELISA O.D. value normalizes against culture O.D. value. Two of the best secretion signals for ABAB were found to be AT and IVS (Table 4; Fig. 15A).

[00248] Due to the unavailability of an auxotrophic mutant strain for *S. boulardii*, another 2 μ m-based plasmid carrying the *aphA1* gene encoding resistance to G418 (pCEV-G4-Km; SEQ ID NO:80; a gift from Lars Nielsen & Claudia Vickers (Addgene plasmid # 46819)) was used

instead of pD1214 plasmids to confirm ABAB secretion in *S. boulardii*. The best two secretion signals for *S. cerevisiae* (AT and IVS) were fused with ABAB genetically and inserted in the pCEV-G4-Km plasmid backbone to generate plasmids pCEV-G4-Km-TEF-AT-hABAB* (SEQ ID NO:81) and pCEV-G4-Km-TEF-IVS-hABAB* (SEQ ID NO:82). Both plasmids were used to transform *S. boulardii* (strain MYA796) and ABAB secretion with AT and IVS in *S. boulardii* was comparable with *S. cerevisiae* as determined by ELISA (Fig. 15B). A further construct, pCEV-G4-Km-TEF-AT-hABAB (SEQ ID NO:83), was prepared which differs from pCEV-G4-Km-TEF-AT-hABAB* in that it contains a molecular cloning site between the AT and hABAB sequence.

[00249] ABAB secretion was then further optimized by yeast codon optimization (yABAB) at the nucleotide level in the construct having the AT secretion signal, producing plasmid pCEV-G4-Km-TEF-AT-yABAB (SEQ ID NO:84). A sequence containing 40 nucleotides between P_{TEF} and ABAB coding sequence was also found to be dispensable for ABAB secretion and removed resulting in plasmid pCEV-G4-Km-TEF-X40-AT-yABAB (SEQ ID NO:85). A further sequence containing two restriction cloning sites between AT and ABAB sequence was found to negatively impact ABAB secretion and therefore this sequence was also omitted (plasmid pCEV-G4-Km-TEF-AT-^{RS}yABAB; SEQ ID NO:115) for subsequent study to maximize ABAB secretion.

[00250] Next, the amount of secretion of the individual monomers was measured and AA6 was found to be secreted the least. To improve AA6 secretion, and thus further optimize ABAB secretion, a panel of key amino acid residues was utilized. A T83N mutation was found to improve AA6 secretion. In addition, *S. boulardii* carrying the hAA6 sequence was found to secrete more AA6 than the one carrying the yeast optimized yAA6 sequence. Therefore, a comparison was undertaken between ABAB carrying the T83N mutation within AA6 (AT-yABAB T83N; plasmid pCEV-G4-Km-TEF-AT-yABAB AA6T83N; SEQ ID NO:116) and ABAB where the yAA6 sequence was replaced by the hAA6 T83N sequence (AT-yABAB hAA6 T83N; plasmid pCEV-G4-Km-TEF-AT-yABAB hAA6T83N, which has the sequence of SEQ ID NO:90 but lacks the coding sequence for c-Myc)) to determine which sequence exhibited better secretion. It was found that there was no significant difference between these constructs and AT-yABAB hAA6 T83N was concluded as the final sequence moving forward. The nucleotide sequence encoding AT-yABAB hAA6 T83N is provided in plasmid pCEV-G4-

Km-TEF-AT-yABAB hAA6T83N-tagless (SEQ ID NO:90). The amino acid sequence of AT-yABAB hAA6 T83N is provided in SEQ ID NO:117.

Generation of an auxotrophic *S. boulardii* strain

[00251] The expression plasmid encoding ABAB can be cloned into the *S. boulardii* strain. The *S. boulardii* strain can tolerate normal body temperature and acidic conditions better than *S. cerevisiae*, which can improve efficacy as a novel oral yeast-based therapeutic strategy. Two modifications to a wild-type *S. boulardii* strain can be made to preserve the *in vivo* stability of the expression plasmid conferred by the yeast *URA3* metabolic selection marker: 1) a diploid auxotrophic mutant carrying a deletion in both chromosomal alleles of *URA3* can be constructed, and 2) the endogenous 2 micron circle can be cured from *S. boulardii* to prevent unintended recombination from interfering with ABAB expression.

[00252] The most straightforward and efficient method for constructing auxotrophic mutants in wild-type *Saccharomyces* strains involves targeted deletion of chromosomally encoded genes by homologous recombination, which occurs at very high frequencies in *Saccharomyces*. Complete deletion of the targeted gene is preferred over selection of spontaneous mutations which can revert back to the wild type. Thus a gene deletion is preferred for the haploid state in *S. cerevisiae* which is typically induced from wild-type diploid via sporulation using a nutritionally poor growth medium and incubating at low temperature (30 °C). However, *S. boulardii* is sporulation deficient and recalcitrant to formation of haploid cells under normal sporulation conditions [64,65]. A two-step process for deletion of both chromosomal gene alleles (e.g. *URA3*) was used in which each deletion step can be selected for. The process is outlined schematically in Fig. 16.

[00253] All chromosomal deletions were carried out by lithium acetate-facilitated genetic transformation [73] of linear DNA deletion cassettes. Lithium acetate-based transformation originated from a *S. cerevisiae* protocol and was found to be compatible with *S. boulardii* although *S. boulardii* was found to be much harder to transform [55,56]. The difference is around 100 fold. Transformation efficiency in *S. cerevisiae* can be improved by adjusting glucose concentration and heat shock time [74]. Therefore various glucose concentrations and heat shock times were incorporated in *S. boulardii* transformation for optimization. The best condition

tested for *S. boulardii* was 2% glucose in preculture and 20 minutes of heat shock time at 42°C and these conditions were used for all transformation procedures in all studies.

[00254] Two deletion cassettes containing the genes *aphA1* and *ble*, which confer resistance to G418 and phleomycin in yeast respectively, were generated by PCR using pCEV-G4-Km (SEQ ID NO:80) and pCEV-G4-Ph (SEQ ID NO:86) (a gift from Lars Nielsen & Claudia Vickers (Addgene plasmid # 46820)) as templates. Both deletion cassettes are flanked by two locus of X-over P1 (loxP) in the same direction, allowing for antibiotic resistance genes spin out using *Cre*-recombinase. 40 base pairs of homologous sequences upstream of *URA3* promoter (P_{URA3}) and downstream of the stop codon of *URA3* were incorporated in PCR primers to generate two final deletion cassettes for site-specific gene deletion in *S. boulardii* (see Fig. 16). The exact sequence and location of *URA3* gene on chromosome V on *S. boulardii* was mapped using *URA3* gene annotation from online-published sequence from *Saccharomyces* genome database (SGD). Selection for crossover 1 replacing the first *URA3* allele with *aphA1* deletion cassette is selected for using resistance to G418 [66]; the second crossover replacing the second *URA3* allele with *ble* deletion cassette is selected for using resistance to phleomycin [75] (Fig. 16). The replacement of both *URA3* alleles with *aphA1* and *ble* deletion cassettes was evidenced by resistance to both antibiotics (data not shown) as well as lack of growth on minimal synthetic medium plates lacking uracil (data not shown). Yeast phenotype was also confirmed by growth on Sabouraud plate with chloramphenicol (100 ug/ml) (data not shown). In addition, three sets of unique primers targeting the *URA3*, *aphA1* or *ble* genes in the *URA3* chromosomal region was designed and performed PCR using wild type (WT), *URA3* Δ ::*aphA1*/*URA3* (1st crossover) and *URA3* Δ ::*aphA1*/ Δ ::*ble* (2nd crossover) genomic DNA as templates. Expected PCR product sizes targeting the *URA3*, *aphA1* or *ble* genes in the *URA3* chromosomal region are 766bp, 1183bp, and 662bp respectively. DNA electrophoresis of PCR products from WT, 1st crossover and 2nd crossover clones using these three sets of unique primers confirmed the absence of *URA3* alleles and integration of the *aphA1* and *ble* deletion cassettes of the 2nd crossover strain.

[00255] The 2nd crossover strain was then transformed with pPL5071_TEF1-Cre_URA3 (pPL5071; SEQ ID NO:95) [76] to remove the *aphA1* and *ble* deletion cassettes. Strain carries pPL5071 expresses *Cre* recombinase constitutively under P_{TEF} . *Cre* recombinase then targets *loxP* sequences flanking the *aphA1* and *ble* deletion cassettes; this causes the excision of the *aphA1* and *ble* deletion cassettes, leaving only one *loxP* site in the *URA3* chromosomal region.

Strains that underwent successful excision of the *aphA1* and *ble* deletion cassettes cannot grow in the presence of either G418 or phleomycin; yet retain the loss of both *URA3* alleles, therefore can only grow on minimal synthetic medium plate in the presence of uracil and showed no growth on minimal synthetic medium plate without uracil supplement.

[00256] Removal of pPL5071 was achieved by growth in YPD and selecting for colonies later grown on minimal synthetic medium containing uracil and the pyrimidine analog 5-fluoro-orotic acid (5-FOA) [77]. Strains possessing pPL5071 carry the *URA3* gene that can synthesize the toxic intermediate 5-fluorodeoxyuridine a potent inhibitor of thymidylate synthetase, which interrupts DNA synthesis and leads to cell death and allows selection of strains that have lost pPL5071. The absence of pPL5071 also was confirmed by pPL5071 specific primers by PCR and DNA electrophoresis of the PCR product.

[00257] The 2 um plasmid is a very stable 6.1 kb plasmid that is ubiquitous in *Saccharomyces* strains. This plasmid confers no selective advantage to the yeast host organism, and it is remarkably stable due to the presence of an efficient *REP1-REP2-STB* plasmid partitioning system [68]. *S. boulardii* strains used also contain this plasmid as confirmed via PCR. To remove the 2 um plasmid, pBIS-GALkFLP-URA3 (SEQ ID NO:87) [67] was used to cure 2 um plasmid, followed by removal with uracil and 5-FOA. Loss of the 2 um plasmid was confirmed by PCR using primers specific for the origin of replication.

[00258] The auxotrophic strain of *S. boulardii* that results from these manipulations is termed *S. boulardii URA3 Δ/Δ*.

Auxotrophic *S. boulardii* Strain for *in situ* Delivery of ABAB

[00259] For constructing the auxotrophic *S. boulardii* strain for *in situ* delivery of ABAB, the *aphA1* cassette of the plasmid pCEV-G4-Km-TEF-X40-AT-yABAB (SEQ ID NO:85) was replaced by the *URA3* cassette from pD plasmid to generate the plasmid pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88). This plasmid was then used to transform *S. boulardii URA3 Δ/Δ*. The resulting strain secretes fully functional ABAB when compared with purified ABAB in a cell toxicity assay (Fig. 17C). Western blotting showed the corresponding ABAB band from *S. boulardii* culture supernatant using α -Llama antibodies conjugated with HRP (Fig. 17D). C-terminus end of ABAB contains c-Myc tag and can be further pulled down by α -c-Myc antibodies (Fig. 17D).

[00260] For empty plasmid (EP) control, AT-yABAB sequence was later removed from pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88) to generate pCEV-URA3-TEF-cMyc (SEQ ID NO:89). *S. boulardii* URA3 Δ/Δ strain transformed with this plasmid results a strain complemented with URA3 but does not secrete ABAB. *S. boulardii* URA3 Δ/Δ strain secreting ABAB also showed no growth inhibition when cultured in YPD containing vancomycin (1mg/ml) (Fig. 17A). This suggests *S. boulardii* can be co-administered with vancomycin typically used to treat CDI patients and secretes ABAB to treat ongoing CDI. In addition, purified ABAB is stable in culture supernatant collected from *S. boulardii* at O.D. 10 over 2 hours period of time suggests secreted ABAB is likely to diffuse out from *S. boulardii* without being degraded.

Safety Assessment of *S. boulardii* Delivered Orally to Antibiotic-treated Mice

[00261] Prior to evaluating whether *S. boulardii* URA3 Δ/Δ expressing ABAB can protect mice in CDI models [20,33,62,78], a safety assessment was performed to determine safe doses of *S. boulardii* in antibiotic-treated mice. In this safety assessment mice were first supplied with an antibiotic cocktail in their daily drinking water for three days and then switched to regular water. One day before oral delivery of *S. boulardii*, mice were injected with clindamycin intraperitoneally. This completes the antibiotic treatment for the mice and *S. boulardii* was then orally delivered to the mice for safety assessment, which includes monitoring of daily weight change and persistence of *S. boulardii* in their stool samples of these antibiotic-treated mice. Mice exhibited no signs of illness and steadily weight increase during 6 days of monitoring when 10^{10} cells of *S. boulardii* were delivered orally consistent with the idea of *S. boulardii* as a GRAS organism. For the subsequent CDI mouse studies, however, only 10^9 cells of *S. boulardii* were given due to the ease of pellet resuspension and less variability of the dosing amount to the mice, which can occur with high viscosity present in resuspension. *S. boulardii* also shows limited colonization in these antibiotic-treated mice GI tracts; three days after the final gavage, no detectable *S. boulardii* were recovered from Sabouroud plate (data not shown).

Protection of *S. boulardii* Expressing ABAB Against Primary CDI in Mice

[00262] Protection of *S. boulardii* expressing ABAB was evaluated using established primary mouse CDI models. *S. boulardii* expressing ABAB was delivered either as preventative or

treatment against primary CDI in mice. In brief, primary CDI was established in mice by supplementing a mixture of antibiotic into their drinking water for three days, and then intraperitoneal injection of clindamycin 24 hours prior to *C. difficile* spore challenge. 10^5 *C. difficile* spores (UK1, a 027/BI/NAP1 epidemic strain) were gavaged in the mice to induce CDI. For preventative evaluation, mice started receiving an oral dose of *S. boulardii* the day after switching to regular drinking water, which continued every day for 7 days. For therapeutic evaluation, mice received an oral dose of *S. boulardii* at 6, 24, 48, and 72 hours after spore challenge. Controls included PBS and *S. boulardii* transformed with an empty plasmid. In both methods, mice receiving *S. boulardii* expressing ABAB were significantly protected against CDI-induced deaths (Figs. 18A and 19A; PBS: negative control; Sb: EP: *S. boulardii* transformed with an empty plasmid; Sb: BAB: *S. boulardii* secreting ABAB). CDI mice typically suffered weight loss with most weight drops around day 2 to day 3 due to diarrhea and gradually recovered. Weights of mice receiving *S. boulardii* expressing ABAB recovered significantly sooner (Figs. 18B and 19B) and had significant reduced percentage of diarrhea incidents after day 2 post challenge (Figs. 18C and 19C).

Protection of *S. boulardii* Expressing ABAB Against Recurrence CDI in Mice

[00263] Protection of *S. boulardii* expressing ABAB was evaluated against recurrence CDI in mice. To induce recurrent CDI, mice were given three days of antibiotic cocktail in their daily drinking water. After three days of antibiotic water, mice were then switched back to drinking regular water. One day before oral delivery of 10^5 *C. difficile* spores (UK1, a 027/BI/NAP1 epidemic strain), mice were injected with clindamycin intraperitoneally. Six hours after spore challenge, regular water was changed to water containing 0.5mg/ml of vancomycin for six days and regular water was switched back again for the rest of study. Mice typically develop signs of CDI after 4 days of vancomycin withdrawal without another *C. difficile* spore challenge. During the course of recurrence model, *S. boulardii* was orally delivered along with vancomycin water once every day for 12 days. This model is used to evaluate protection efficacy of *S. boulardii* expressing ABAB for preventing CDI recurrence in mice. Survival rate, weight loss and diarrhea incident of these mice were monitored on a daily basis. Controls included PBS and *S. boulardii* transformed with an empty plasmid. Mice receiving *S. boulardii* expressing ABAB were significantly protected against recurrence-induced CDI deaths (Fig. 20A; PBS: negative control;

Sb: EP: *S. boulardii* transformed with an empty plasmid; Sb: BAB: *S. boulardii* secreting ABAB). Similar to primary CDI mice, recurrent CDI mice also typically suffered weight loss with most weight drops around day 4 to day 5 after vancomycin water withdrawal. Mice receiving *S. boulardii* expressing ABAB were significantly protected from weight loss (Fig. 20B) and had significant reduced percentage of diarrhea recurrence incidents (Fig. 20C).

Stability Optimization of ABAB Cassette Through Chromosomal Integration

[00264] Genome editing using a CRISPR-Cas9 based system has been recently demonstrated both in *S. cerevisiae* and *S. boulardii* [79-81]. In addition, large fragment deletion can be achieved by targeting two guide sequences simultaneously [82]. Foreign genes are typically more steadily maintained when integrated into chromosomes versus introduced via plasmids when there is no selection pressure. However, chromosomal integration often requires multiple rounds of integration to achieve high copies. A protocol reported in a recent publication overcame this hurdle through targeting multiple copies of common sequences such as δ sites in *S. cerevisiae* genome through CRISPR-induced double strand breaks and achieved concurrent integration of large fragments in these sites [83]. DNA double strand break can be repaired either by non-homologous end joining or homologous recombination; however, when endogenous homologous sequences are present, host preferentially uses homologous sequences to repair DNA double strand break by homologous recombination [83].

[00265] δ sites are long terminal repeats (LTRs) belong to the Ty element I and II and are the most abundant LTRs in *S. cerevisiae*. There are five types of Ty elements (1-5) represented by the class II transposon (retrotransposon) that is more commonly found in *S. cerevisiae*. It is estimated that there are about 51 retrotransposons (Ty1-5) and 251 δ sites across *S. cerevisiae* genomes [84]. Such δ sites are appealing target sequences for ABAB expression cassette integration into *S. boulardii* chromosomes. However, much less is known about δ sites in *S. boulardii*. Therefore, Ty1-H3 (Genbank accession no. M18706) [84] was first used as a probe to survey Ty1-2 elements in *S. boulardii* strain MYA796 (ATCC, Manassas, VA) (draft genome obtained from NCBI) to identify possible Ty1-2 elements and their δ sites in the *S. boulardii* genome. Surprisingly, no full Ty1-2 elements were found in MYA796. A total of 57 δ sites were found; this includes 44 full δ sites and 12 partial sites as well as a partial Ty element containing 1 full δ site identified across all 16 chromosomes (Table 12).

Table 12 – Number of δ sites and their distribution on MYA796 chromosomes

	Full δ site	Full Ty1, 2 elements	Partial δ site 60 < X < 200 bp	Partial Ty1, 2 element with full δ site
Ch I	0	0	1	0
Ch II	0	0	0	0
Ch III	1	0	0	0
Ch IV	5	0	1	1
Ch V	2	0	1	0
Ch VI	2	0	0	0
Ch VII	8	0	1	0
Ch VIII	2	0	0	0
Ch IX	3	0	0	0
Ch X	3	0	1	0
Ch XI	0	0	0	0
Ch XII	8	0	1	0
Ch XIII	2	0	1	0
Ch XIV	1	0	0	0
Ch XV	2	0	4	0
Ch XVI	5	0	1	0
Total	44	0	12	1

[00266] Due to *S. boulardii* diploid state; there are about 114 δ sites across the *S. boulardii* genome. To allow simple multiple δ site targeting by CRISPR, all 57 δ site sequences were compiled for multiple sequence alignment using MUSCLE to identify protospacer adjacent motif (PAM) sites that present in high numbers among the 57 δ sequences. Two PAM sites were chosen based on the highest number of δ sequences having uniformity in protospacers as the upstream and downstream sequences. The sequences of these PAM sites are illustrated in Figure 21 and the specific sequences are as follows:

PAM Site I

TGTTGGAATAAAAATCAACTATCATCTACTAACTAGTATTTACGTTACTAGTATATTA
TCATATACGGTGTTAGAAGATGACGCAAATGATGAGAAATAGTCATCTAAATTAGT
GGAAGCTGAAAC (SEQ ID NO:93)

PAM Site II

AATATTTATAGAATTGTGTAGAATTGCAGATTCCCTTTTATGGATTCCCTAAATCCTCG
AGGAGAACTTCTAGTATATCTACATACTAATATTATAGCCTTAATC (SEQ ID NO:94).

[00267] In both Pam Site I and Pam Site II, the sequences underscored by a dashed line correspond to the upstream homologous sequences; the sequences underscored by a single line correspond to the 20 bp protospacers; the sequences underscored by a double line correspond to the PAM sequences; the sequences underscored by a wavy line correspond to the downstream homologous sequences.

[00268] These two PAM sites, accompanied by their common upstream and downstream homologous sequences within the δ sites, allow simple chromosomal integration of ABAB expression cassettes into *S. boulardii* genomes. ABAB integration cassettes containing homologous recombination sequences were generated by PCR using primers containing the upstream homologous sequences with the last three nucleotides removed at the 3' end and the downstream homologous sequences with the first two nucleotides removed at the 5' end and the corresponding annealing sequences needed for PCR using plasmid pCEV-G4-Km-TEF-AT-yABAB hAA6T83N-tagless as template (SEQ ID NO:90).

[00269] PCR products of the ABAB integration cassette with CRISPR plasmids contain the corresponding guide sequence (pCRI-Sb- δ 1 (SEQ ID NO:91) and pCRI-Sb- δ 2 (SEQ ID NO:92)) were then cotransformed with *S. boulardii* for ABAB integrations into chromosomes independently and sequentially to target PAM site I and PAM site II. The ratio of PCR product to CRISPR plasmid was found to be important for generating successful integration clones (Fig. 22A; ITG^{low} versus ITG^{high}). In addition, a repeat transformation of the highest ABAB secretion clone from ITG^{high} group with the same integration cassette and CRISPR plasmid did not further improve the overall ABAB secretion of independent clones (Fig. 22A; 2nd ITG^{high}). ABAB secretion of the highest ABAB secretion clone (C^{RISPR}-2) from ITG^{high} group was then further improved by cotransforming the second set of ABAB integration cassette containing the homologous recombination sequences and its corresponding guide sequence in CRISPR plasmid targeting site II (Fig. 22A). Two highest ABAB secretion clones, C^{RISPR}-3 and C^{RISPR}-4 were selected. ABAB secretion amount and stability over time of these four representative clones are shown in Fig. 22B. A preliminary mouse CDI study was performed. However, C^{RISPR}-4 was found to be not better than previously M^{-/-}:ABAB clone that showed protection in a number of mouse CDI models (Fig. 23).

*

*

*

*

[00270] While the invention has been described with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various modifications may be made without departing from the spirit and scope of the invention. The scope of the appended claims is not to be limited to the specific embodiments described.

REFERENCES

[00271] All patents and publications mentioned in this specification are indicative of the level of skill of those skilled in the art to which the invention pertains. Each cited patent and publication is incorporated herein by reference in its entirety. All of the following references have been cited in this application:

1. Cloud, J. & Kelly, C.P. Update on Clostridium difficile associated disease. *Curr Opin Gastroenterol* **23**, 4-9 (2007).
2. Kelly, C.P. & LaMont, J.T. Clostridium difficile--more difficult than ever. *N Engl J Med* **359**, 1932-1940 (2008).
3. Barbut, F., *et al.* Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. *J Clin Microbiol* **38**, 2386-2388 (2000).
4. Hassoun, A. & Ibrahim, F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. *Am J Geriatr Pharmacother* **5**, 48-51 (2007).
5. Shahani, L. & Koirala, J. Intravenous immunoglobulin in treatment of Clostridium difficile colitis. *BMJ Case Rep* **2012**(2012).
6. Saito, T., *et al.* Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. *J Antimicrob Chemother* **66**, 1096-1099 (2011).
7. Abougergi, M.S. & Kwon, J.H. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. *Dig Dis Sci* **56**, 19-26 (2011).
8. Sokol, H., Maury, E., Seksik, P., Cosnes, J. & Beaugerie, L. Single immunoglobulin infusion can reverse hemodynamic failure associated with severe Clostridium difficile colitis. *Am J Gastroenterol* **104**, 2649-2650 (2009).
9. Lowy, I., *et al.* Treatment with monoclonal antibodies against Clostridium difficile toxins. *N Engl J Med* **362**, 197-205 (2010).
10. Louie, T.J., *et al.* Fidaxomicin versus vancomycin for Clostridium difficile infection. *The New England journal of medicine* **364**, 422-431 (2011).
11. Rao, K. & Young, V.B. Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. *Infectious disease clinics of North America* **29**, 109-122 (2015).

12. Vyas, D., Aekka, A. & Vyas, A. Fecal transplant policy and legislation. *World journal of gastroenterology : WJG* **21**, 6-11 (2015).
13. Tonna, I. & Welsby, P.D. Pathogenesis and treatment of Clostridium difficile infection. *Postgrad Med J* **81**, 367-369 (2005).
14. McFarland, L.V., Elmer, G.W. & Surawicz, C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. *The American journal of gastroenterology* **97**, 1769-1775 (2002).
15. O'Neill, G.L., Beaman, M.H. & Riley, T.V. Relapse versus reinfection with Clostridium difficile. *Epidemiol Infect* **107**, 627-635 (1991).
16. Wilcox, M.H., Fawley, W.N., Settle, C.D. & Davidson, A. Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection? *J Hosp Infect* **38**, 93-100 (1998).
17. Johnson, S., Adelman, A., Clabots, C.R., Peterson, L.R. & Gerding, D.N. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. *J Infect Dis* **159**, 340-343 (1989).
18. Tang-Feldman, Y., Mayo, S., Silva Jr, J., Jr. & Cohen, S.H. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea. *J Clin Microbiol* **41**, 3413-3414 (2003).
19. Johnson, S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. *Int J Antimicrob Agents* **33 Suppl 1**, S33-36 (2009).
20. Sun, X., *et al.* Mouse relapse model of Clostridium difficile infection. *Infection and immunity* **79**, 2856-2864 (2011).
21. Seal, D., *et al.* Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. *Eur J Clin Microbiol* **6**, 51-53 (1987).
22. Kuehne, S.A., *et al.* The role of toxin A and toxin B in Clostridium difficile infection. *Nature* (2010).
23. Lyras, D., *et al.* Toxin B is essential for virulence of Clostridium difficile. *Nature* **458**, 1176-1179 (2009).
24. Libby, J.M. & Wilkins, T.D. Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. *Infection and immunity* **35**, 374-376 (1982).

25. Katchar, K., *et al.* Association between IgG2 and IgG3 subclass responses to toxin A and recurrent *Clostridium difficile*-associated disease. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* **5**, 707-713 (2007).
26. Ghose, C., *et al.* Transcutaneous immunization with *Clostridium difficile* toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. *Infection and immunity* **75**, 2826-2832 (2007).
27. Sougioultzis, S., *et al.* *Clostridium difficile* toxoid vaccine in recurrent *C. difficile*-associated diarrhea. *Gastroenterology* **128**, 764-770 (2005).
28. Kyne, L., Warny, M., Qamar, A. & Kelly, C.P. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea. *Lancet* **357**, 189-193 (2001).
29. Leav, B.A., *et al.* Serum anti-toxin B antibody correlates with protection from recurrent *Clostridium difficile* infection (CDI). *Vaccine* **28**, 965-969 (2010).
30. Fernie, D.S., Thomson, R.O., Batty, I. & Walker, P.D. Active and passive immunization to protect against antibiotic associated caecitis in hamsters. *Dev Biol Stand* **53**, 325-332 (1983).
31. Kim, P.H., Iaconis, J.P. & Rolfe, R.D. Immunization of adult hamsters against *Clostridium difficile*-associated ileocectitis and transfer of protection to infant hamsters. *Infection and immunity* **55**, 2984-2992 (1987).
32. Lyerly, D.M., Bostwick, E.F., Binion, S.B. & Wilkins, T.D. Passive immunization of hamsters against disease caused by *Clostridium difficile* by use of bovine immunoglobulin G concentrate. *Infection and immunity* **59**, 2215-2218 (1991).
33. Wang, H., *et al.* A chimeric toxin vaccine protects against primary and recurrent *Clostridium difficile* infection. *Infection and immunity* **80**, 2678-2688 (2012).
34. Hamers-Casterman, C., *et al.* Naturally occurring antibodies devoid of light chains. *Nature* **363**, 446-448 (1993).
35. van der Linden, R., *et al.* Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of *Lama glama*. *J Immunol Methods* **240**, 185-195 (2000).

36. Harmsen, M.M. & De Haard, H.J. Properties, production, and applications of camelid single-domain antibody fragments. *Appl Microbiol Biotechnol* **77**, 13-22 (2007).
37. Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R. & Muyldermans, S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. *FEBS Lett* **414**, 521-526 (1997).
38. van der Linden, R.H., *et al.* Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. *Biochim Biophys Acta* **1431**, 37-46 (1999).
39. Dumoulin, M., *et al.* Single-domain antibody fragments with high conformational stability. *Protein Sci* **11**, 500-515 (2002).
40. Hussack, G., Hirama, T., Ding, W., Mackenzie, R. & Tanha, J. Engineered single-domain antibodies with high protease resistance and thermal stability. *PloS one* **6**, e28218 (2011).
41. Yang, Z., *et al.* A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant *Clostridium difficile* infection in mice. *The Journal of infectious diseases* **210**, 964-972 (2014).
42. McFarland, L.V. Systematic review and meta-analysis of *Saccharomyces boulardii* in adult patients. *World J. Gastroenterol.* **16**, 2202-2222 (2010).
43. Elmer, G.W., McFarland, L.V., Surawicz, C.M., Danko, L. & Greenberg, R.N. Behaviour of *Saccharomyces boulardii* in recurrent *Clostridium difficile* disease patients. *Aliment. Pharmacol. Ther.* **13**, 1663-1668 (1999).
44. Surawicz, C.M., *et al.* The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin. Infect. Dis.* **31**, 1012-1017 (2000).
45. McFarland, L.V., *et al.* A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *Jama* **271**, 1913-1918 (1994).
46. Czerucka, D., Piche, T. & Rampal, P. Review article: yeast as probiotics -- *Saccharomyces boulardii*. *Alimentary pharmacology & therapeutics* **26**, 767-778 (2007).
47. Sougioultzis, S., *et al.* *Saccharomyces boulardii* produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. *Biochemical and biophysical research communications* **343**, 69-76 (2006).

48. Qamar, A., *et al.* *Saccharomyces boulardii* stimulates intestinal immunoglobulin A immune response to *Clostridium difficile* toxin A in mice. *Infection and immunity* **69**, 2762-2765 (2001).
49. Chen, X., *et al.* *Saccharomyces boulardii* inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against *Clostridium difficile* toxin A-induced enteritis. *The Journal of biological chemistry* **281**, 24449-24454 (2006).
50. Barc, M.C., *et al.* Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of *Saccharomyces boulardii*. *Anaerobe* **14**, 229-233 (2008).
51. Gorlani, A., de Haard, H. & Verrips, T. Expression of VHHs in *Saccharomyces cerevisiae*. *Methods in molecular biology* **911**, 277-286 (2012).
52. Khatri, I., *et al.* Gleaning evolutionary insights from the genome sequence of a probiotic yeast *Saccharomyces boulardii*. *Gut Pathog.* **5**, 30 (2013).
53. Batista, T.M., Marques, E.T., Jr., Franco, G.R. & Douradinha, B. Draft Genome Sequence of the Probiotic Yeast *Saccharomyces cerevisiae* var. *boulardii* Strain ATCC MYA-796. *Genome announcements* **2**, 578-579 (2014).
54. Hamedi, H., *et al.* Generation of a uracil auxotroph strain of the probiotic yeast *Saccharomyces boulardii* as a host for the recombinant protein production. *Avicenna journal of medical biotechnology* **5**, 29-34 (2013).
55. Hudson, L.E., *et al.* Functional heterologous protein expression by genetically engineered probiotic yeast *Saccharomyces boulardii*. *PLoS One* **9**, e112660 (2014).
56. Douradinha, B., *et al.* Novel insights in genetic transformation of the probiotic yeast *Saccharomyces boulardii*. *Bioengineered* **5**, 21-29 (2014).
57. Fietto, J.L., *et al.* Molecular and physiological comparisons between *Saccharomyces cerevisiae* and *Saccharomyces boulardii*. *Canadian journal of microbiology* **50**, 615-621 (2004).
58. Martins, F.S., *et al.* Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. *The Journal of general and applied microbiology* **51**, 83-92 (2005).
59. Martins, F.S., Veloso, L.C., Arantes, R.M. & Nicoli, J.R. Effects of yeast probiotic formulation on viability, revival and protection against infection with *Salmonella*

- enterica* ssp. *enterica* serovar Typhimurium in mice. *Lett. Appl. Microbiol.* **49**, 738-744 (2009).
60. Wu, D., Teng, D., Wang, X., Dai, C. & Wang, J. *Saccharomyces boulardii* prevention of the hepatic injury induced by *Salmonella* Enteritidis infection. *Can. J. Microbiol.* **60**, 681-686 (2014).
61. Elmer, G.W. & Corthier, G. Modulation of *Clostridium difficile* induced mortality as a function of the dose and the viability of the *Saccharomyces boulardii* used as a preventative agent in gnotobiotic mice. *Can. J. Microbiol.* **37**, 315-317 (1991).
62. Chen, X., *et al.* A mouse model of *Clostridium difficile*-associated disease. *Gastroenterology* **135**, 1984-1992 (2008).
63. Pawlowski, S.W., *et al.* Murine model of *Clostridium difficile* infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. *The Journal of infectious diseases* **202**, 1708-1712 (2010).
64. McFarland, L.V. *Saccharomyces boulardii* is not *Saccharomyces cerevisiae*. *Clin. Infect. Dis.* **22**, 200-201 (1996).
65. Edwards-Ingram, L., *et al.* Genotypic and physiological characterization of *Saccharomyces boulardii*, the probiotic strain of *Saccharomyces cerevisiae*. *Appl. Environ. Microbiol.* **73**, 2458-2467 (2007).
66. Panchal, C.J., Whitney, G.K. & Stewart, G.G. Susceptibility of *Saccharomyces* spp. and *Schwanniomyces* spp. to the aminoglycoside antibiotic G418. *Appl. Environ. Microbiol.* **47**, 1164-1166 (1984).
67. Tsalik, E.L. & Gartenberg, M.R. Curing *Saccharomyces cerevisiae* of the 2 micron plasmid by targeted DNA damage. *Yeast* **14**, 847-852 (1998).
68. Chan, K.M., Liu, Y.T., Ma, C.H., Jayaram, M. & Sau, S. The 2 micron plasmid of *Saccharomyces cerevisiae*: a miniaturized selfish genome with optimized functional competence. *Plasmid* **70**, 2-17 (2013).
69. Brake, A.J., *et al.* Alpha-factor-directed synthesis and secretion of mature foreign proteins in *Saccharomyces cerevisiae*. *Proceedings of the National Academy of Sciences of the United States of America* **81**, 4642-4646 (1984).
70. Porro, D., Sauer, M., Branduardi, P. & Mattanovich, D. Recombinant protein production in yeasts. *Molecular biotechnology* **31**, 245-259 (2005).

71. Chung, B.H., Nam, S.W., Kim, B.M. & Park, Y.H. Highly efficient secretion of heterologous proteins from *Saccharomyces cerevisiae* using inulinase signal peptides. *Biotechnology and bioengineering* **49**, 473-479 (1996).
72. Hahm, M.S. & Chung, B.H. Secretory expression of human growth hormone in *Saccharomyces cerevisiae* using three different leader sequences. *Biotechnology and Bioprocess Engineering* **6**, 306-309 (2001).
73. Gietz, R. D. & Schiestl, R. H. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. *Nat. Protoc.* **2**, 31–4 (2007).
74. Konishi, T. & Harata, M. Improvement of the transformation efficiency of *Saccharomyces cerevisiae* by altering carbon sources in pre-culture. *Biosci. Biotechnol. Biochem.* **78**, 1090–1093 (2014).
75. Gatignol, A., Baron, M. & Tiraby, G. Phleomycin resistance encoded by the *ble* gene from transposon Tn 5 as a dominant selectable marker in *Saccharomyces cerevisiae*. *MGG Mol. Gen. Genet.* **207**, 342–348 (1987).
76. Macdonald, C. & Piper, R. C. Puromycin- and methotrexate-resistance cassettes and optimized Cre-recombinase expression plasmids for use in yeast. *Yeast* **32**, 423–438 (2015).
77. Boeke, J. D., LaCroute, F. & Fink, G. R. A positive selection for mutants lacking orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. *Mol Gen Genet* **197**, 345–346 (1984).
78. Yang, Z. *et al.* Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from *Clostridium difficile* infection. *Pathog. Dis.* **74**, ftw078 (2016).
79. DiCarlo, J. E. *et al.* Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucleic Acids Res.* **41**, 4336–43 (2013).
80. Bao, Z. *et al.* Homology-Integrated CRISPR-Cas (HI-CRISPR) System for One-Step Multigene Disruption in *Saccharomyces cerevisiae*. *ACS Synth. Biol.* **4**, 585–594 (2015).
81. Liu, J.-J. *et al.* Metabolic engineering of a probiotic *Saccharomyces boulardii*. *Appl. Environ. Microbiol.* AEM.00057-16 (2016). doi:10.1128/AEM.00057-16
82. Hao, H. *et al.* Large fragment deletion using a CRISPR/Cas9 system in *Saccharomyces cerevisiae*. (2016). doi:10.1016/j.ab.2016.07.008.This

83. Shi, S., Liang, Y., Zhang, M. M., Ang, E. L. & Zhao, H. A highly efficient single-step, markerless strategy for multi-copy chromosomal integration of large biochemical pathways in *Saccharomyces cerevisiae*. *Metab. Eng.* **33**, 19–27 (2016).
84. Kim, J. M. *et al.* Transposable Elements and Genome Organization : A Comprehensive Survey of Retrotransposons Revealed by the Complete *Saccharomyces cerevisiae*. *Genome Research*. 8(5): 464–478 (1998).
85. Bao Z, Xiao H, Liang J, Zhang L, Xiong X, Sun N, Si T, Zhao H. Homology-Integrated CRISPR – Cas (HI-CRISPR) System for One-Step Multigene Disruption in *Saccharomyces cerevisiae*. *ACS Synth Biol*. 4(5):585-94 (2015).
86. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucleic Acids Res* 41:4336–43 (2013).
87. Liu J-J, Kong II, Zhang G-C, Jayakody LN, Kim H, Xia P-F, Kwak S, Sung BH, Sohn J-H, Walukiewicz HE, Rao C V., Jin Y-S. Metabolic engineering of a probiotic *Saccharomyces boulardii*. *Appl Environ Microbiol*. 82(8):2280-7 (2016).
88. Shi S, Liang Y, Zhang MM, Ang EL, Zhao H. A highly efficient single-step, markerless strategy for multi-copy chromosomal integration of large biochemical pathways in *Saccharomyces cerevisiae*. *Metab Eng* 33:19–27 (2016).

WHAT IS CLAIMED IS:

1. An engineered strain of *Saccharomyces* yeast that produces a tetra-specific, tetrameric binding agent, wherein the binding agent comprises linked first, second, third and fourth V_HH peptide monomers, and wherein the V_HH peptide monomers independently have binding specificity for an epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB).
2. The engineered strain of yeast of claim 1, wherein the first, second, third and fourth V_HH peptide monomers each has binding specificity for a different epitope.
3. The engineered strain of yeast of claim 1, wherein two of the V_HH peptide monomers have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers have binding specificity for epitopes of TcdB.
4. The engineered strain of yeast of claim 1, wherein the V_HH peptide monomers independently have binding specificity for an epitope in the glucosyltransferase domain, cysteine protease domain, translocation domain or receptor binding domain of TcdA or TcdB.
5. The engineered strain of yeast of claim 1, wherein the binding agent is ABAB, wherein the first and third monomers have binding specificity for epitopes of TcdA and the first and third monomers are V_HH peptide monomers AH3 (SEQ ID NO:7) and AA6 (SEQ ID NO:5), respectively, and wherein the second and fourth monomers have binding specificity for epitopes of TcdB and the second and fourth monomers are V_HH peptide monomers 5D (SEQ ID NO:1) and E3 (SEQ ID NO:3), respectively.
6. The engineered strain of yeast of claim 5, wherein the ABAB binding agent comprises the amino acid sequence set forth in SEQ ID NO:19, or a sequence variant having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.
7. The engineered strain of yeast of claim 5, wherein the ABAB binding agent further comprises an N-terminal secretion signal selected from the AT secretion signal (MRFPSIFTAVLFAASSALA (SEQ ID NO:99)) and the IVS secretion signal (MLLQAFLFLLAGFAAKISA (SEQ ID NO:103)).
8. The engineered strain of yeast of claim 5, wherein the ABAB binding agent is expressed from a plasmid within the yeast, wherein the ABAB binding agent comprises the amino acid sequence set forth in SEQ ID NO:107, or a sequence variant having at least 95%

sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.

9. The engineered strain of yeast of claim 8, wherein the plasmid is pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88).

10. The engineered strain of yeast of claim 5, wherein ABAB binding agent coding sequence is integrated into a chromosome of the yeast, wherein the ABAB binding agent comprises the amino acid sequence set forth in SEQ ID NO:109, or a sequence variant having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.

11. The engineered strain of yeast of any one of claims 1-10, wherein the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

12. A pharmaceutical formulation comprising a engineered strain of *Saccharomyces* yeast of any one of claims 1-11 and a pharmaceutically acceptable carrier or diluent.

13. A method of preparing the engineered strain of yeast of any one of claims 1-9, comprising (a) transforming a strain of *Saccharomyces* yeast with an expression vector encoding the binding agent, and (b) screening the yeast of (a) for production of the binding agent.

14. A method of preparing the engineered strain of yeast of claim 10, comprising (a) chromosomally integrating a polynucleotide sequence encoding the binding agent into the genome of the strain of *Saccharomyces* yeast, and (b) screening the yeast of (a) for production of the binding agent.

15. The method of claim 13 or 14, wherein the engineered strain of *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

16. The method of claim 13 or 14, wherein the screening is performed using an immunoassay.

17. The method of claim 13, wherein the expression vector is plasmid pCEV-URA3-TEF-AT-yABAB-cMyc (SEQ ID NO:88).

18. The method of claim 14, wherein chromosomal integration is performed via:
(a) amplifying a polynucleotide sequence encoding the ABAB binding agent from plasmid pCEV-G4-Km-TEF-AT-yABAB hAA6T83N-tagless (SEQ ID NO:90) using primers containing (i) nucleic acid sequence homologous to a selected yeast chromosomal integration site

and (ii) nucleic acid sequence homologous to regions 5' and 3' of ABAB binding agent coding sequence of the plasmid, to produce an integration cassette,

(b) transforming yeast with the integration cassette produced in (a) with pCRI-Sb- δ 1 (SEQ ID NO:91) or pCRI-Sb- δ 2 (SEQ ID NO:92) to induce a double stranded break within the corresponding yeast chromosomal delta sites under conditions promoting spontaneous integration of the integration cassette into the site of the double stranded break,

(c) screening the transformed yeast of (b) for production of the ABAB binding agent.

19. The method of claim 18, wherein the screening is performed using an immunoassay.

20. A method of treating or preventing a disease symptom induced by *C. difficile* in a subject comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 1-10 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

21. A method of neutralizing *C. difficile* toxin TcdA and/or TcdB in a subject infected by *C. difficile* comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 1-10 to a subject having *C. difficile* infection.

22. A method of treating or preventing *C. difficile* infection in a subject comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 1-10 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

23. A method of maintaining normal bowel function in a subject having a *C. difficile* infection comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 1-10 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

24. The method of any one of claims 20-23, wherein the engineered strain of yeast is in a pharmaceutical formulation comprising the engineered strain of yeast and a pharmaceutically acceptable carrier or diluent.

25. The method of claim 21, where the neutralizing is partial or full neutralization.

26. The method of claim 22, further comprising administering a therapeutically-effective amount of an antibiotic to the subject.

27. The method of any one of claims 20-23, wherein the therapeutically-effective amount of the engineered strain of yeast is between 10 ug/kg and 100 mg/kg of the engineered strain of yeast per body weight of the subject.

28. The method of any one of claims 20-23, wherein the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

29. The method of any one of claims 20-28, wherein the engineered strain of yeast is administered to the subject orally, nasally or rectally.

30. The method of claim 20, wherein the disease symptom induced by *C. difficile* is diarrhea.

31. An engineered strain of *Saccharomyces* yeast that produces a V_HH peptide binding agent comprising at least one V_HH peptide monomer, wherein each V_HH peptide monomer independently has binding specificity for a unique epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB).

32. The engineered strain of *Saccharomyces* yeast of claim 31, wherein the V_HH peptide binding agent comprises two linked V_HH peptide monomers.

33. The engineered strain of *Saccharomyces* yeast of claim 31, wherein the V_HH peptide binding agent comprises three linked V_HH peptide monomers.

34. The engineered strain of *Saccharomyces* yeast of claim 31, wherein the V_HH peptide binding agent comprises four linked V_HH peptide monomers.

35. The engineered strain of *Saccharomyces* yeast of claim 34, wherein two of the V_HH peptide monomers have binding specificity for epitopes of TcdA and two of the V_HH peptide monomers have binding specificity for epitopes of TcdB.

36. The engineered strain of *Saccharomyces* yeast of any one of claims 31-35, wherein the V_HH peptide monomers are selected from the group consisting of 5D (SEQ ID NO:1), E3 (SEQ ID NO:3), AA6 (SEQ ID NO:5) and AH3 (SEQ ID NO:7) V_HH peptide monomers, or sequence variants thereof having at least 95% sequence identity thereto, and wherein the sequence variant retains TcdA and/or TcdB binding specificity, or the sequence variant retains toxin neutralizing activity, or both.

37. The engineered strain of *Saccharomyces* yeast of any one of claims 32-35, wherein the V_HH peptide monomers are linked using linkers independently selected from linker-1 (SEQ ID NO:9), linker-2 (SEQ ID NO:11), and linker-3 (SEQ ID NO:13).

38. The engineered strain of *Saccharomyces* yeast of 37, wherein variant amino acids of the sequence variant are located in framework regions of the V_HH peptide monomers.

39. The engineered strain of *Saccharomyces* yeast of any one of claims 31-38, wherein the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

40. A method of treating or preventing a disease symptom induced by *C. difficile* in a subject comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 31-39 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

41. A method of neutralizing *C. difficile* toxin TcdA and/or TcdB in a subject infected by *C. difficile* comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 31-39 to a subject having *C. difficile* infection.

42. A method of treating or preventing *C. difficile* infection in a subject comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 31-39 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

43. A method of maintaining normal bowel function in a subject having a *C. difficile* infection comprising administering a therapeutically-effective amount of one or more engineered strains of yeast of any one of claims 31-39 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

44. The method of any one of claims 40-43, wherein the engineered strain of yeast is in a pharmaceutical formulation comprising the engineered strain of yeast and a pharmaceutically acceptable carrier or diluent.

45. The method of claim 41, where the neutralizing is partial or full neutralization.

46. The method of claim 42, further comprising administering a therapeutically-effective amount of an antibiotic to the subject.

47. The method of any one of claims 40-43, wherein the therapeutically-effective amount of the engineered strain of yeast is between 10 ug/kg and 100 mg/kg of the engineered strain of yeast per body weight of the subject.

48. The method of any one of claims 40-43, wherein the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

49. The method of any one of claims 40-48, wherein the engineered strain of yeast is administered to the subject orally, nasally or rectally.

50. The method of claim 40, wherein the disease symptom induced by *C. difficile* is diarrhea.

51. An engineered strain of *Saccharomyces* yeast that produces a therapeutic protein having binding specificity for a unique epitope of *Clostridium difficile* toxin A (TcdA) or toxin B (TcdB), or both.

52. The engineered strain of *Saccharomyces* yeast of claim 51, wherein the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

53. The engineered strain of *Saccharomyces* yeast of claim 51 or 52, wherein the therapeutic protein is an antibody.

54. The engineered strain of *Saccharomyces* yeast of claim 51 or 52, wherein the strain of *Saccharomyces* yeast is engineered by (a) transforming a strain of *Saccharomyces* yeast with an expression vector encoding the therapeutic protein, and (b) screening the yeast of (a) for production of the therapeutic protein.

55. The engineered strain of *Saccharomyces* yeast of claim 51 or 52, wherein the strain of *Saccharomyces* yeast is engineered by (a) chromosomally integrating a polynucleotide sequence encoding the therapeutic protein into the genome of the strain of *Saccharomyces* yeast, and (b) screening the yeast of (a) for production of the therapeutic protein.

56. The method of claim 54 or 55, wherein the screening is performed using an immunoassay.

57. A method of treating or preventing a disease symptom induced by *C. difficile* in a subject comprising administering a therapeutically-effective amount of an engineered strain of yeast of claim 51 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

58. A method of neutralizing *C. difficile* toxin TcdA and/or TcdB in a subject infected by *C. difficile* comprising administering a therapeutically-effective amount of an engineered strain of yeast of claim 51 to a subject having *C. difficile* infection.

59. A method of treating or preventing *C. difficile* infection in a subject comprising administering a therapeutically-effective amount of an engineered strain of yeast of claim 51 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

60. A method of maintaining normal bowel function in a subject having a *C. difficile* infection comprising administering a therapeutically-effective amount of an engineered strain of yeast of claim 51 to a subject having *C. difficile* infection or a risk of developing *C. difficile* infection.

61. The method of any one of claims 57-60, wherein the engineered strain of yeast is in a pharmaceutical formulation comprising the engineered strain of yeast and a pharmaceutically acceptable carrier or diluent.

62. The method of claim 58, where the neutralizing is partial or full neutralization.

63. The method of claim 59, further comprising administering a therapeutically-effective amount of an antibiotic to the subject.

64. The method of any one of claims 57-60, wherein the therapeutically-effective amount of the engineered strain of yeast is between 10 ug/kg and 100 mg/kg of the engineered strain of yeast per body weight of the subject.

65. The method of any one of claims 57-60, wherein the *Saccharomyces* yeast is *S. cerevisiae* or *S. boulardii*.

66. The method of any one of claims 57-60, wherein the engineered strain of yeast is administered to the subject orally, nasally or rectally.

67. The method of claim 57, wherein the disease symptom induced by *C. difficile* is diarrhea.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5A




Figure 5B




Figure 6





Figure 7



IgG-ABAB half life: 5-7 days;
ABBA half life: 7.8h

Figure 8A




Figure 8B




Figure 9A




Figure 9B




Figure 10A




Figure 10B





Figure 11







Figure 12

Figure 13

A



B





Figure 14

A



B





Figure 15

A



B




Figure 16




Figure 17






Figure 18

A



B



C






Figure 19

A



B



C






Figure 20

A



B



C




Figure 21





Figure 22

A



B






Figure 23

A



B



C




Figure 20

C

